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Abstract 
Gliotoxin is a secondary metabolite that is produced by several species of fungi, and is toxic 
to mammalian cells. It is immunosuppressive, affects antigen presentation by macrophages, 
and causes apoptosis of some cells. Gliotoxin is an epipolythiodioxopiperazine molecule and 
contains an internal disulfide bridge that is highly reactive and essential for its toxicity.  
Suggested mechanisms of action include modification of thiol groups of cysteine residues in 
target proteins by generating oxidative stress or through covalent modification. The goal of 
this project was to develop mass spectrometry methods to detect protein modification by 
gliotoxin. Creatine kinase was used as a model protein. The measured mass of creatine 
kinase from 45 spectra gave a mean of 42,944 ± 24 which was consistent with the predicted 
mass of creatine kinase.  A tryptic digest of creatine kinase indicated ions consistent with 
the predicted masses of the four cys-containing peptides including abundant ions at m/z 
794, 1130 and 2870 and an ion at low intensity at 4373. The reaction of creatine kinase with 
gliotoxin showed a time dependent reaction that after 14 h was consistent with formation 
of a gliotoxin adduct. Reduction of the product with dithiothreitol released creatine kinase. 
Analysis of the tryptic peptides using MALDI mass spectrometry indicated complex 
modification of cysteines possibly including formation of a mixed disulfide adduct, 
intramolecular disulfides of CK, and sulfur oxidation products. Further analysis using the 
ICAT (isotope-coded affinity tag) method suggested modification of Cys-254 and Cys-283 by 
gliotoxin. Preliminary experiments examined the effects of gliotoxin on HL-60 cells using 
ICAT. Proteins of gliotoxin-treated and untreated cells were labeled with Heavy and Light 
ICAT reagents. Potential ICAT pairs were detected in the mass spectrum as a preliminary 
search for proteins affected by gliotoxin. The results indicate that ICAT labeling should be an 
effective strategy for characterization of the protein targets of gliotoxin. 
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ACN                                Acetonitrile 
CHCA                             α-Cyano-4-hydroxycinnamic acid 
CK                                   Creatine kinase 
Cys                           Cysteine 
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ETP                                 Epidithiodioxopiperazine 
GTX                                Gliotoxin 
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ICAT                               Isotope-coded affinity tag 
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MS                                 Mass spectrometry 
MS/MS                         Tandem mass spectrometry 
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1. Introduction 
Gliotoxin is an immunosuppressive cytotoxin that is synthesised by diverse species of fungi 
including Aspergillus fumigates, Gliocladium fimbriatum, Trichoderma virens, Penicillium 
spp, and Candida albicans as a secondary metabolite (Gardiner, Waring & Howlett, 2005, 
Rezanka, Sobotka, Spizek & Sigler, 2006). Many filamentous fungi synthesise secondary 
metabolites which are not necessary for growth, although they generally have critical 
biological roles (Cramer et al., 2006, Munday, 1989). GTX is a hydrophobic molecule and 
belongs to the ETP (epipolythiodioxopiperazine) class of fungal metabolites (Chai & Waring, 
2000). ETPs are non-polar and contain an internal disulfide bridge which is crucial for their 
biological activity (Gardiner et al., 2005, Jones & Hancock, 1988). The internal disulfide 
bridge enables ETPs to bind to the thiol group of cysteine residues of proteins or to act as a 
redox active molecules (Waring, Sjaarda & Lin, 1995). ETP toxins have antibacterial, antiviral, 
immunosuppressive and antineoplastic activities (Jordan & Cordiner, 1987, Gardiner et al., 
2005).  GTX is a virulence factor of the human pathogen A. fumigatus that affects T cells and 
antigen presenting cells (Mullbacher & Eichner, 1984, Yamada, Kataoka & Nagai, 2000). The 
immunosuppressive characteristics of GTX involve effects on macrophages and mature 
lymphocytes (Waring, Eichner & Mullbacher, 1988). Mullbacher and Eichner (1984) showed 
that GTX inhibits the phagocytotic activity of macrophages. Another study showed that 
treatment of macrophages with GTX resulted in DNA fragmentation and subsequently 
apoptosis of macrophages (Waring, Eichner, Mullbacher & Sjaarda, 1988). GTX inhibits T cell 
activation by preventing antigen presentation and promoting apoptosis in monocytes. GTX 
also leads to apoptosis in some other cells such as hepatic stellate cells and HL-60 cell lines 
(Stanzani et al., 2005, Hur et al., 2008). Apoptosis may be related to interaction with 
mitochondrial proteins or inhibition of activation of transcription factor NFκB (Stanzani et 
al., 2005, Hur et al., 2008). NFκB is crucial for inflammatory immune responses and 
therefore inhibition of activation of this protein may be partly responsible for the 
immunosuppressive effects of GTX (Choi et al., 2007, Pahl et al., 1996, Gardiner et al., 2005). 
It has also been shown that increasing intracellular calcium levels are associated with 
necrosis of GTX treated thymocytes and this change may be due to interactions of GTX with 
redox sensitive calcium channels on the plasma membrane (Gardiner et al., 2005).  
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There is evidence of morphological and cell adhesion changes in rat liver cell cultures 
immediately after addition of GTX (Jordan & Pedersen, 1986). These cellular changes might 
be produced by interaction of GTX with membrane proteins or cytoskelatal microfilaments 
including actin or actin binding proteins (Jordan & Pedersen, 1986). Orr et al. (2004) 
suggested that GTX has antifibrogenic and apoptosis effects on rat liver cells through a thiol 
redox dependent interaction.  
1.1 GTX structure 
GTX (Fig. 1) (C13H14O4N2S2, molecular mass 326.4) is the most studied ETP. It contains a 
disulfide-bridged piperazinedione ring (Fridrichsons & Mathieson, 1967, Reeves, Murphy, 
Daly & Kavanagh, 2004). The toxicity of GTX is dependent on its disulfide bond (Jordan & 
Pedersen, 1986, Srinivasan et al., 2006).  
 
 
 
Figure 1: Structure of GTX  
Structure of GTX from CSID: 5988, http://www.chemspider.com/Chemical-
Structure.5988.html (accessed 05:08, Oct 27, 2012). 
 
1.2 Biosynthesis of GTX 
Biosynthetic ETPs are derived from at least one aromatic amino acid.  GTX is derived from 
phenylalanine and serine as precursor amino acids (Gardiner et al., 2005). Secondary 
metabolites of fungi that have more than one amino acid are generally produced by non-
ribosomal peptide synthetases. The complete genome sequence of A. fumigatus showed 
that the non-ribosomal peptide synthetase enzymes that synthesise GTX usually have genes 
clustered in the genome (Gardiner et al., 2005). Several genes (gli genes) have been 
identified related to the biosynthesis of GTX (Balibar & Walsh, 2006) including gliZ, a 
transcriptional regulator of GTX production that encodes the Zn(II)2Cys6 binuclear 
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transcription factor. Substitution of the gliZ gene with a marker gene caused no detectable 
GTX biosynthesis and failure to express the other gli cluster genes (Bok et al., 2006, Schrettl 
et al., 2010). Additionally mutation in the gliP gene resulted in failure to make GTX (Fox & 
Howlett, 2008). These genes are activated when secondary metabolism commences in fungi 
(Rementeria et al., 2005). LeaA is a methyltransferase that possibly is involved in regulation 
of these genes (Stack, Neville & Doyle, 2007). It has been shown that gli genes are repressed 
in the absence of GTX, indicating that GTX regulates its own biosynthesis (Cramer et al., 
2006). 
 
1.3 Toxicity of GTX 
Understanding of the mechanism of action of ETPs and factors affecting their reactivity is 
important because it might provide insight into new approaches to control the toxic effects 
of ETPs (Jones & Hancock, 1988). The toxicity characteristic of ETPs like GTX are because of 
the internal disulfide bridge that is suggested to act in two ways: (1) covalent modification 
by formation of mixed disulfides with proteins that contain susceptible thiol groups (Fig. 2) 
and/or (2) formation of reactive oxygen species (Fig. 3) through redox cycling (oxidative 
stress) (Munday, 1989, Waring et al., 1995).  
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1.3.1 Covalent modification 
GTX interacts with some proteins through the formation of disulfide bonds with thiol 
residues. Known target proteins include creatine kinase (Hurne, Chai & Waring, 2000), 
alcohol dehydrogenase (Waring et al., 1995), and glutaredoxin (Srinivasan et al., 2006).  
 
 
 
 
 
Figure 2: Schematic for covalent modification of proteins by GTX 
The figure shows the proposed covalent modification of proteins by GTX. GTX interacts with 
proteins via covalent binding to the thiol group of cysteine. One sulfur of GTX is adducted to 
the cysteine forming a mixed disulfide. The second sulfur of GTX may be present as free 
thiol.  
GTX is known to possess antibacterial, antiviral and antifungal properties that are thought to 
be dependent on the disulfide bond (Fukuyama, Nakatsuka & Kishi, 1981). The toxicity of 
GTX for bacteria has been proposed to involve selective binding to thiol groups of proteins 
on the cytoplasmic membrane. A study by Jones and Hancock (1988) of the antibiotic 
activity of GTX showed that a Salmonella typhimurium mutant with a deficiency in synthesis 
of outer-membrane polysaccharide was sensitive to GTX, and they proposed that GTX binds 
to cytoplasmic membranes. GTX prevents viral RNA replication through the inhibition of 
reverse transcriptase in viruses (Miller, Milstrey & Trown, 1968). 
1.3.2 Redox cycling 
Munday (1989) proposed that the toxicity of ETPs is dependent on redox cycling of the 
disulfide in the presence of oxygen and subsequent generation of reactive oxygen species 
such as superoxide or hydrogen peroxide (H2O2) (Fig. 3) that can directly damage DNA and 
   HS    GTX     S 
             Cysteine     S 
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proteins and subsequently stimulate apoptosis. Superoxide (O2
.−) can give rise to hydrogen 
peroxide and hydroxyl radical (HO.) which is thought to be the most toxic species. 
 
 
 
 
Figure 3: Redox cycling of GTX            
Proposed scheme for recycling of GTX between the disulfide and dithiol is accompanied by 
production of superoxide, hydrogen peroxide and finally hydroxyl radical (adapted from 
Gardiner et al., 2005). 
GTX exists almost exclusively in its reduced form in animal cells (Bernardo, Brasch, Chai & 
Waring, 2003). Oxidation of intracellular GTX resulted in its rapid efflux from the cell and its 
entry to neighbouring cells (Bernardo et al., 2003). The disulfide bridge is vital for GTX 
toxicity, thus any alterations to it such as removing sulfur atoms prevents its activity 
(Gardiner et al., 2005). For example, treatment with reducing agents such as glutathione or 
dithiothreitol (DTT) resulted in loss of GTX activity (Grovel et al., 2006). In contrast to the 
proposed production of superoxide by redox cycling, Choi et al. (2007) demonstrated anti-
oxidation effects of GTX that they proposed to be due to interactions with thioredoxin. 
 
1.4 Effects of GTX on model proteins 
1.4.1 GTX reaction with CK 
Creatine kinase (CK) is an essential enzyme in cellular energy homeostasis and metabolism 
(Zhao, Yan, Liu & Zhou, 2007). CK is expressed by a variety of cells and tissues. It catalyses 
the reversible reaction of the conversion of creatine and consumes ATP to produce 
phosphocreatine and ADP (Zhao et al., 2007, Wu et al., 2011). Therefore, CK has an 
important role in the formation and maintenance of phosphocreatine that can be converted 
to ATP in a short time in cells (Cantwell et al., 2001). The CK homodimer has eight SH groups 
(Dithiol form) (Disulfide form) 
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in its structure and it is thought that two of these SH groups are more reactive than others 
(Hou & Zhou, 1996). The activity of CK can be inhibited by thiol specific agents and reactive 
oxygen species (Hurne et al., 2000). Therefore, in this project CK from rabbit muscle was 
used as an experimental model protein for use of mass spectrometry to examine interaction 
of GTX with protein cysteine residues. CK from rabbit muscle functions as a non-covalently 
bound dimer that comprises two identical monomers containing 4 cysteines (Cys-74, Cys-
146, Cys-254 and Cys-283) in each of its 42 kDa monomers (Hurne et al., 2000). The 
monomers show non-identical behaviour because the thiol groups on the two monomers 
react at different rates (Price & Hunter, 1976). Cys-283 is the only reactive cysteine in CK 
that is close to the active site of the enzyme (Hurne et al., 2000). The crystal structure of CK 
shows that Cys-283 and Cys-74 are physically close (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4: Structure of monomer of CK showing the positions of the cysteine residues 
The image was produced using the spdbv.exe programme. The crystal structure of CK 
suggests that Cys-283 is near to the active site of the protein. Cys-74 is located between α 
helices 4 and 5, Cys-283 is located between β sheets 7 and 8, Cys-254 is in α helix 10, and 
Cys-146 is found between β sheets 1 and 2 (Rao, Bujacz & Wlodawer, 1998). 
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Inactivation of CK by GTX is a complex process, potentially involving formation of a GTX-CK 
mixed disulfide that can also act as an intermediate to form intramolecular disulfides of CK. 
Hurne et al. (2000) proposed that inactivation of the enzyme occurs because of disulfide 
bond formation on two cysteines of CK. They postulated that an initial mixed disulfide can 
give rise to a fully oxidized CK internal disulfide between Cys-283 and 74. They proposed 
that GTX initially binds to a thiol of CK as an intermediate (A) (Fig. 5) and then reacts with an 
adjacent thiol to make a disulfide bond in CK (B). Tryptic digests of CK that had reacted with 
[35S] GTX contained radiolabeled peptides from reaction with Cys-254, to a lesser extent 
with Cys-283, and with Cys-146 in lower amounts. No reaction with Cys-74 was detected. 
Reducing agents such as DTT prevent inactivation of CK by GTX via direct reduction of GTX 
(Grovel et al., 2006), or possibly by reduction of the protein-GTX mixed disulfide. 
  
 
 
 
 
Figure 5: Proposed mechanism for CK inhibition by GTX  
Proposed formation of a mixed disulfide between CK Cys-283 and GTX followed by 
formation of an internal disulfide between Cys-283 and 74. Adapted from Hurne et al. 
(2000). 
 
 
 
 
 
 
 
(A) 
 
(B) 
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1.4.2 GTX reaction with glutaredoxin                     
Glutaredoxin (GRX1) is an antioxidant enzyme that exhibits specific catalysis of reduction of 
protein-glutathionyl mixed disulfides, and it has important roles in homeostasis of 
intracellular thiol status (Biswas, Chida & Rahman, 2006). GTX is both a substrate and an 
inhibitor of GRX1. In the presence of GSH, GTX forms a mixed disulfide with GSH that may 
be a possible substrate for GRX1. In the absence of GSH, GTX inhibits GRX1 in a time and 
concentration dependent reaction that requires reduced GRX1 (dithiol), oxidized GTX and 
oxygen (Srinivasan et al., 2006). Analysis of the reaction product by mass spectrometry 
showed the production of an adduct consistent with a disulfide between one molecule of 
GRX1 and one molecule of GTX. This reaction product was 64 Da less than the expected 
mass, indicating elimination of two sulfur atoms either in the mass spectrometer, or lost 
during the enzyme initiated reaction. Inhibition of GRX1 was reversed by denaturation of 
GRX1 with urea and then reduction with DTT, suggesting the breakage of the mixed disulfide 
bound between GRX1 and GTX. It is thought that the reaction initiates between GTX sulfurs 
and Cys-22 in the active site of GRX1 (Srinivasan et al., 2006). 
 
1.5 Mass spectrometry 
Mass spectrometry (MS) can be used to identify proteins and their post translational 
modifications and to measure changes in protein abundance between different samples 
(Ashcroft, 2003, Mann & Kelleher, 2008). Mass spectrometry uses size-based separation of 
charged molecules. In MS, gas phase ions in a vacuum are separated based on their mass to 
charge (m/z) ratio. Two techniques are commonly used to produce protein or peptide ions 
in the gas phase for MS analysis: matrix assisted laser desorption ionization (MALDI) and 
electrospray ionization (ESI) (Ashcroft, 2003). ESI ionizes proteins or peptides out of solution 
and generates multiply charged ions for each protein or peptide (Aebersold & Mann, 2003). 
In the MALDI method, a protein or peptide sample is mixed with a UV absorbing matrix and 
co-crystallised onto a MALDI target plate and then the sample is irradiated with a UV laser in 
the mass spectrometer to generate mainly singly charged ions in the gas phase. In time of 
flight (TOF) analysis the ion masses can be measured based on the time taken to reach the 
detector (Vanlaere et al., 2008).  
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Two methods are used for protein identification using mass spectrometry (Fig. 6). Peptide 
mass fingerprinting (PMF) is carried out by digesting proteins (trypsin is often the enzyme of 
choice) and matching a list of experimental peptide masses obtained from MS with the 
masses present in a database (Siepen, Keevil, Knight & Hubbard, 2007). Tandem mass 
spectrometry (MS/MS) includes isolation of generated peptide ions and fragmentation by 
energetic collision with gas molecules in the mass spectrometer to give sequence-based ions 
that can be interpreted either de novo or searched against sequence databases (Aebersold 
& Mann, 2003).  
Trypsin cleaves peptides after lysine or arginine residues except when these residues are 
subsequent to a proline residue (Siepen et al., 2007).  Tryptic digestion is suitable for MALDI 
analysis because the generated peptides have positively charged C-terminal lysine or 
arginine amino acids that migrate as [M+1] ions in a mass spectrometer. Arginine containing 
peptides typically provide better signals in MALDI compared to lysine containing peptides 
(Siepen et al., 2007) because of ionization differences between these two amino acids 
(Ashcroft, 2003).  
 
 
 
 
 
Figure 6: Schematic of a generic MS-based proteomics methodology 
The figure shows a common approach for identification of proteins. Initially purified protein 
is digested (often with trypsin) to produce peptide fragments. The generated peptides are 
analyzed by MS to measure peptide masses, or by MS/MS, and resultant masses are 
searched against databases to identify proteins.  
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1.6 ICAT labeling 
ICAT (isotope-coded affinity tag) reagents are used in a gel free and MS based approach to 
identify and quantify proteins and oxidant sensitive thiols in proteins (Sethuraman et al., 
2004). The ICAT reagent has a reactive iodoacetamide group that reacts with free cysteine 
thiols. In this method, two protein samples are labeled with either Heavy or Light ICAT 
reagents that have four components (Fig. 7): (1) a biotin affinity tag that helps selection of 
cysteine-containing peptides and simplifies the peptide mixture; (2) cleavable linker, the 
biotin tag is removed by cleaving the linker with acid and the ICAT-labeled peptides are 
purified using an avidin cartridge; (3) the isotope coded tag which identifies labeled proteins 
with Heavy reagent tag including 9 heavy isotopes or Light reagent tag containing no heavy 
isotope, this mass difference (9 Da) allows comparison of free thiols in samples by means of 
MS; (4) an iodoacetamide group that reacts with cysteine sulfhydryls (Fu et al., 2008).  
 
 
 
 
 
Figure 7: ICAT reagent 
The figure shows the components of ICAT reagent. (Image source: Handbook for Methods of 
Applied Biosystems ICAT reagents). 
 
After labeling of proteins with acid cleavable ICAT reagents, the labeled samples are 
combined and then digested with typsin and purified by chromatographic methods (cation 
exchange and avidin chromatography). The resolution of the separation improves by 
increasing either the number of fractions or the number of chromatographic separations 
(Hsu & Chen, 2005). Subsequently peptides are analyzed by MS to identify and quantify free 
labeled cysteines, while modified cysteines lose ICAT labels, therefore this method 
 
11 
 
measures the relative abundance of cysteinyl peptides by measuring the signal intensities in 
MS (Page, Griffiths, Bleackley & MacGillivray, 2006, Hood, Veenstra & Conrads, 2004) (Fig. 
8). Tandem MS can then be used to identify the peptides and the parent proteins. ICAT has 
been used to examine the oxidation of CK by H2O2 (Sethuraman et al., 2004). Cys-283, but 
not Cys-146 was shown to be sensitive to oxidation by H2O2. This result was similar to the 
conclusion of Hurne et al. (2000) that GTX reacts with Cys-283 of CK. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic of a quantitative proteomic strategy using ICAT and MS (Page et al., 
2006). License Number for permission: 3022281111339  
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1.7 Goals 
The goal of this project was to use MS and ICAT to examine the reaction of GTX with protein 
cysteines. The enzyme CK was selected as a model to examine the reaction of protein 
cysteines with GTX. CK was exposed to GTX, and MS was used to examine the reaction 
products. DTT was used as a reducing agent to test reversal of the modification. Based on 
previous results (Hurne et al., 2000) it was expected that Cys-283 would be reactive 
including formation of a mixed disulfide adduct with GTX, and that Cys-74 might also show 
change due to formation of a Cys-283-Cys-74 internal disulfide. H2O2 was used as an oxidant 
to identify oxidant-sensitive cysteines of CK. Preliminary experiments were carried out to 
establish conditions for use of ICAT to detect proteins modified by GTX in HL-60 cells. 
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2. Methods 
2.1 Mass spectrometry 
 Analysis of proteins and peptides was carried out using an AB SCIEX TOF/TOFTM 5800 mass 
spectrometer (Applied Biosystems, Foster City, CA) controlled by TOF/TOFTM Explorer TM 
software. MALDI spectra were obtained by mixing tryptic digests of proteins with CHCA (α-
cyano-4-hydroxycinnamic acid) matrix, or proteins with sinapinic acid (3, 5-dimethoxy-4-
hydroxycinnamic acid) matrix, followed by crystallisation of a µL of the sample on a target 
MALDI plate. The samples were irradiated with UV light in the vacuum chamber of the 
MALDI mass spectrometer. 
2.1. 1 Calibration of the MALDI-TOF  
The MALDI mass spectrometer was calibrated using standard peptides and proteins of 
known molecular weight. For each analysis spectra were obtained first for calibrant and 
then for samples on the same plate (external calibration).  The spectra were analyzed using 
Data Explorer software version 5.1 (Applied Biosystems, Foster City, CA). 
 
2.2 MALDI-TOF MS 
2.2.1 Preparation of CK for MALDI-TOF analysis using the dried droplet method  
CK from rabbit muscle was purchased from Roche Diagnostics GmbH (Penzberg, Germany; 
catalogue number 10127566001) and prepared in water as a 1 mg/mL solution 
(approximately 25 µM according to the 43 kDa mass of CK).  Native CK was reduced by 
addition of DTT (Merck, Darmstadt, Germany) (3 mg/mL) to a final concentration of 20 mM, 
followed by incubation at 50 0C for 30 min. In some experiments, the product was then 
alkylated by addition of iodoacetamide (IAA) (GE Healthcare, Buckinghamshire, UK) (9.25 
mg/mL) to a final concentration of 50 mM and incubation at room temperature for 30 min 
in the dark. The samples of native CK, alkylated CK, and reduced-alkylated CK were prepared 
in sinapinic acid matrix by mixing 1 µL of sample with 1, 2, 5 or 10 µL of sinapinic acid matrix 
solution. Aliquots (1 µL) were then spotted onto a MALDI plate and left to dry allowing 
crystal formation before inserting the sample plate into the MALDI vacuum chamber. The 
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sinapinic acid matrix solution was prepared by suspending 10 mg of matrix in 1 mL ACN 
(acetonitrile) (minimum 99.5%, Sigma Chemical Company, MO): 0.1 %TFA (trifluoroacetic 
acid, Fluka Chemie GmbH, Switzerland) (1:1). This mixture was then centrifuged at full speed 
(12,100 x g) for 5 min in a MiniSpin (Eppendorf) centrifuge. The supernatant was transferred 
to a clean tube and the remaining sediment containing undissolved crystals was discarded.  
Sinapinic acid matrix was used to analyze proteins because it generates less fragment ions 
than CHCA and therefore facilitates measurement of masses greater than 10 kDa. For 
calibration of protein masses, 1 µL of the Cal 3 peptide mixture (Applied Biosystems) was 
suspended in 100 µL of the sinapinic acid matrix and 1 µL aliquots were then spotted onto 
the MALDI plate. The spectra were calibrated against Cal 3 containing thioredoxin (11,674 
m/z), apomyoglobin (horse) (16,952 m/z), and apomyoglobin (33,904 m/z). Peak matching 
conditions for calibration of MALDI spectra were a signal to noise ratio greater than or equal 
to 10, mass tolerance of ± 90 Da, and a minimum of 2 matched calibrants. 
2.2.1.1 MS spectra acquisition 
To obtain spectra, the MALDI mass spectrometer was used in the positive ion linear mode 
with detector voltage of 1.950 kV, laser pulse rate 400 Hz, delay time 2430 nsec, and 
velocity 600 µm/sec. The spectra were acquired over a mass range of 10,000 to 100,000 Da 
using 1000 shots per spectrum with an approximate laser intensity range of 5500 to 6200. 
2.2.2 Tryptic digests 
Samples of native CK, alkylated CK, and reduced-alkylated CK were digested with trypsin 
(Modified sequencing grade, Roche Diagnostics GmbH, catalogue number 11418025001). A 
1 µg aliquot of trypsin was reconstituted in 20 µL of 50 mM ammonium bicarbonate.  Five-
fold diluted samples were prepared by adding 10 µL of native CK, alkylated CK, and reduced-
alkylated CK to 40 µL of ammonium bicarbonate. Ten microliters of these dilutions were 
mixed with 2 µL of trypsin followed by incubation at 37 0C for at least 3 h or overnight. The 
tryptic digests were prepared in CHCA matrix (Sigma) by mixing 1 µL of digests with 1, 2, 5 or 
10 µL of CHCA matrix solution, followed by spotting 1 µL aliquots onto the MALDI plate. The 
CHCA matrix was made by mixing 10 mg of CHCA in 1 mL ACN: 0.1% TFA (1:1). This was 
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centrifuged at full speed in a MiniSpin centrifuge for 5 min. The supernatant was removed 
and transferred to a clean tube and the remainder with undissolved crystals was discarded.  
CHCA is a “hot” matrix that is appropriate for peptide detection (less than 4 kDa). To achieve 
accurate calibration of monoisotopic peptide masses from tryptic digests of CK, or modified 
CK, Cal 2 standard (Sigma) was used as a calibrant. This was done by adding 1 µL of Cal 2 to 
100 µL of CHCA matrix and then 1 µL aliquots were spotted onto the MALDI plate. The 
acquired spectra were calibrated against the Cal 2 spectra containing a bradykinin fragment 
1-7 (monoisotopic m/z 757.3997), human angiotenisin II (monoisotopic m/z 1046.5423), 
P14R (synthetic peptide) (monoisotopic m/z 1533.8582), human ACTH fragment 18-39 
(monoisotopic m/z 2465.1989), and bovine insulin oxidized B chain (monoisotopic m/z 
3494.6513). Peak matching conditions for calibration of MALDI-MS were a signal to noise 
ratio greater than or equal to 200, mass tolerance of ± 0.5 m/z, a minimum of 4 matched 
peaks, and maximum outlier error was 3 ppm. 
2.2.2.1 MS spectra acquisition  
To obtain spectra for spotted peptides, the MALDI-TOF mass spectrometer was used in 
positive ion reflector mode with CID off, final detector voltage 1.800 kV, laser pulse rate 400 
Hz, delay time 140 nsec, and velocity 600 µm/sec. The spectra were acquired in a mass 
range of 700 to 5000 Da with 400 shots per spectrum. The laser was fired in a random and 
uniform pattern with an approximate intensity range of 2900 to 3500.  
 
2.2.3 Reaction of CK with GTX  
In order to examine the effects of GTX on CK, GTX (from Gliocladium fimbriatum) was used 
(Sigma Chemical Company, MO, catalogue number G9893). CK was prepared in water as a 
25 µM solution and GTX was made as a 15 mM solution by dissolving 5 mg of GTX in 1 mL of 
DMSO (dimethyl sulfoxide). The reaction of the CK with GTX was carried out using CK (25 µg) 
incubated with GTX (10 µg) at 37 0C in a water bath overnight. The control was CK incubated 
with DMSO.  
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2.2.3.1 Reduction and alkylation 
In some experiments CK or modified CK was alkylated with IAA. An aliquot (1 µL) of IAA 
(9.25 mg/mL) was added to 10 µL CK solution followed by incubation at room temperature 
for 30 min in the dark. To examine reduced CK, 10 µL of DTT (3 mg/mL) was added to CK 
followed by incubation at 50 0C for 30 min. GTX-treated CK, reduced GTX-treated CK and 
alkylated GTX-treated CK were prepared in sinapinic acid matrix by mixing 1 µL of samples 
with 1, 2, 5 or 10 µL of sinapinic acid matrix solution. Then 1 µL aliquots were placed on the 
MALDI plate and allowed to dry.  
GTX-treated CK and alkylated GTX-treated CK were digested with trypsin (see Section 2.2.2). 
Tryptic digests were prepared in CHCA matrix by mixing 1 µL of digests with 1, 2, 5 or 10 µL 
of CHCA matrix solution and were then subjected to MALDI analysis.  
 
2.2.4 Treatment of CK with H2O2 
Hydrogen peroxide (H2O2) 30% (Perhydrol®) was purchased from Merck (Darmstadt, 
Germany, catalogue number 107209) new for this project. CK (100 µg) was incubated with 
10 µL of hydrogen peroxide at room temperature for 10 min, with untreated CK as control. 
The reaction was stopped by addition of 0.1 µg of bovine liver catalase (Sigma) prepared as 
a 1 mg/mL solution. In some experiments, the sample was alkylated by mixing 10 µL of the 
reaction product with 1 µL of IAA (9.25 mg/mL) and reacted at room temperature for 1 h in 
the dark. 
 
2.2.5 ICAT labeling of CK 
ICAT reagents were from Applied Biosystems (Cleavable ICAT® Reagent Kit for protein 
labeling, Monoplex Version). CK was made up in 50 mM Tris (pH 8.3) as a 25 µM solution (1 
mg/mL). A 15 mM GTX solution was made by dissolving 5 mg of GTX in 1 mL of DMSO. CK 
(25 µg) was exposed to GTX (10 µg) or control conditions at 37 0C overnight, approximately 
14 h. The entire sample of the GTX-treated CK was transferred into a vial of Heavy ICAT 
reagent in ACN (20 µL) and the control CK was transferred into a vial of Light ICAT reagent.  
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These two vials were incubated at 37 0C for 2 h in a water bath in the dark. The ICAT-labeled 
protein samples were mixed to give a 1:1 ratio sample and then digested with 25 µg of 
trypsin by incubating at 37 0C for 10-14 h. The tryptic peptides were purified using a cation 
exchange cartridge (Part Number: 4326752) according to the Applied Biosystems Cleavable 
ICAT® Reagent protocol to remove excess labeling reagents and trypsin. The ICAT-labeled 
peptides were collected from the cation exchange column by eluting the peptides with a 
cation exchange buffer (collecting a single fraction). The collected peptides were then 
further purified using an avidin affinity cartridge (Part Number: 4326746) for selective 
isolation of ICAT-labeled peptides. The unlabeled peptides were washed from the affinity 
cartridge with an ICAT affinity buffer wash and the ICAT-labeled peptides were then eluted 
with an affinity buffer. The eluted affinity-purified ICAT-labeled peptides were evaporated 
to dryness in a centrifugal vacuum concentrator then suspended in ICAT cleavage reagents. 
The cleaving reagent A and the cleaving reagent B were mixed in a 95:5 ratio then 90 µL of 
this was added to the ICAT-labeled peptides followed by incubating at 37 0C for 2 h. The 
sample was once again dried by evaporation and peptides were suspended in 20 µL of 0.1 % 
TFA. The unlabeled peptides were also dried and dissolved in 20 µL of 0.1 % TFA. The 
peptide samples were used either directly for MALDI analysis or after desalting and 
concentrating using Eppendorf PerfectPure® C-18 Tips.  
 
2.2.6 Purifying and concentration of peptide samples before MALDI analysis 
The samples of labeled and unlabeled peptides were cleaned up and desalted using 10 µL 
Eppendorf PerfectPure® C-18 Tips. First, the tips were washed by aspirating 100% ACN 
solution through the tips and discarding the solvent at least three times. The tip was then 
washed by aspirating and discarding 50% ACN/ 0.1 % TFA in HPLC-grade water solution 
three times, followed by washing with 0.1% TFA. Next, the peptides were bound to the tip 
by aspirating and dispensing at least 15 times.  The tip was washed by aspirating and 
discarding 0.1% TFA in HPLC-grade water four times. Finally, the peptides were eluted into 
1.5 µL of 70% ACN /0.1% TFA in HPLC-grade water by aspirating and expelling 15 times to 
maximize retrieval of the original peptides.  This sample was dried in a centrifugal vacuum 
concentrator.  For MALDI analysis, the dried peptides were dissolved in 20 µL of 0.1 % TFA 
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and then were prepared in the CHCA matrix by mixing 1 µL of peptides with 1, 2, 5 or 10 µL 
of the CHCA matrix.   
2.2.7 Matching tryptic peptides to the CK sequences 
CK was identified by means of peptide mass fingerprinting. CK was digested with trypsin to 
generate peptide fragments, and then tryptic peptide fragments were desalted using C-18 
Zip Tips (see Section 2.2.6). The peptides were separated by HPLC (Tempo TM LC MALDI). For 
HPLC analysis, the dried peptides were dissolved in 20 µL of buffer A, 98% H2O/ 0.1% TFA/ 
2% ACN. This was centrifuged at full speed for 10 min and then transferred to an 
autosampler vial in the Tempo TM LC Spotter. The Tempo performs one gradient capillary 
HPLC separation and automatically spots the sample along with matrix onto a MALDI target 
plate for analysis. The obtained sequences were searched against the NCBI non-redundant 
database via Mascot algorithm version 2.3 (see the search result in Appendix D).  
2.2.7.1 MS/MS of CK peptides 
To acquire MS/MS (tandem mass spectrometry) spectra for tryptic peptides of CK, the 
MALDI was used in 1 kV positive reflector mode, with CID and metastable suppressor on. 
The laser was fired in a random and uniform pattern with intensity of 4662 and a pulse rate 
of 1000 Hz. Once five sub-spectra were collected the acquisition of spectra was stopped and 
the final spectra were collected after a total of 500 laser shots per spectrum. 
2.2.7.2 MS/MS spectra calibration 
The MS/MS spectra were calibrated against the known fragment ion masses from the 
monoisotopic human ACTH fragment 18-39 (2465.1989 Da), which is an isolated precursor 
ion. Peak matching parameters for calibration included a signal to noise ratio of 50, mass 
tolerance of 200 ppm, a minimum of 15 matched peaks, final detector voltage of 1.950 kV, 
and maximum outlier error of 2 Da. 
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2.2.7.3 MS/MS monoisotopic precursor selection 
The criteria selected for the interpretation method for MS/MS included minimum mass of 
800 and maximum mass of 3000 Da, 20 maximum precursors, and excluded precursors 
within 200 resolution. The exclusion list is shown in Appendix A. 
2.2.7.4 Matching of peptide sequences to the NCBI database  
Peptide mass fingerprints and acquired sequences from MS/MS were imported into Protein 
Pilot TM software and searched against the NCBI non- redundant protein sequence database 
using the Mascot algorithm. The search parameters included mammalian taxonomy, 
monoisotopic masses, a +1 peptide charge, one missed trypsin cleavage, variable 
modification by methionine oxidation, MS/MS fragment tolerance of 0.1 Da, and precursor 
tolerance of 0.05 Da. 
 
2.2.8 Mammalian cell culture 
2.2.8.1 Culture conditions 
HL-60 human promyelocytic leukemic cells were obtained from Professor John H. Miller’s 
group, School of Biological Sciences, Victoria University of Wellington and were cultured in 
DMEM/F12 (Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12 (Ham)) (GIBCO®, 
Grand Island, NY, USA) supplemented with 10% FCS in the presence of 100 units/mL 
penicillin and 100 units/mL streptomycin. The cells were maintained in a humidified 
atmosphere at 37 0C in 5% CO2 in air and were passaged when they reached about 80% 
confluency. 
2.2.8.2 GTX treatment  
GTX (from Gliocladium fimbriatum) stock solution 5 mg/mL in DMSO was stored at -20 0C. 
When cultured HL-60 cells reached approximately 80% confluency, the cells were seeded 
into flasks containing 9x106 cells, each with a total volume of 10 mL. Some flasks were 
treated with 2, 10 or 50 µg of GTX. Control flasks included DMSO or untreated controls.  
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2.2.8.3 Cell viability using trypan blue exclusion 
To evaluate the cytotoxicity of GTX in HL-60 cultures the viability of cells was determined 
using a hemocytometer and a trypan blue exclusion test. To examine the viability of cells, 10 
µL of HL-60 cells were stained with 10 µL of 0.4% trypan blue dye and then 10 µL of this 
mixture was added to the hemocytometer. Dead cells took up dye and were blue but live 
cells excluded dye.  
2.2.8.4 Monitoring HL-60 cell morphological change 
Morphological changes of HL-60 cells were examined at 0, 1, 2 and 24 h after GTX treatment 
using phase contrast microscopy and photographed with 10x and 20x objectives using a 
CC12 Soft Image System camera that was connected to an Olympus IX51 microscope, and 
Olympus Cell A Imaging software. 
2.2.8.5 Harvesting HL-60 cells  
Cells were centrifuged at 300 g for 5 min. Supernatants were removed and discarded and 
cell pellets resuspended in 2 mL of ice-cold PBS that had been flushed with nitrogen to 
displace oxygen. Cells were centrifuged again, supernatants were removed, and the cells 
were resuspended in 1 mL of PBS and transferred into 1.5 mL microcentrifuge tubes. Cells 
were centrifuged at 300 g (SIGMA 1-14 Laboratory Table Top Microcentrifuge) for 5 min, 
supernatants were removed and nitrogen was flushed gently into the tubes. Cell pellets 
were stored at -80 0C until required. 
2.2.8.6 HL-60 cell lysis and protein extraction 
The cell pellets were resuspended in lysis buffer (30 mM Tris-Cl, 7 M urea, 2 M thiourea, 4% 
(w/v) CHAPS) with an approximate volume of 60 µL per 3.6 x 106 cells and vortexed for 30 
min at 4 0C.  Samples were then centrifuged at 16,000 g for 15 min at 4 0C. Supernatants 
were removed and stored at -20 0C for later use. Twenty five micrograms of the obtained 
proteins from untreated (control) and 10 µg GTX-treated samples were reconstituted with 
the labeling buffer and labeled using Light and Heavy ICAT respectively using the methods 
described in Section 2.2.5. Free cysteine residues were directly labeled in the control and 
GTX-treated samples without the reduction of disulfide bonds to maintain the thiol redox-
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states. The ICAT-labeled peptides were dried, cleaned up by Zip Tipping and then were 
analyzed by MALDI MS. 
2.2.8.7 Searching against databases 
MS/MS and parent ion data was exported into peaklist format and imported into PEAKS 
software for de novo sequencing (Zhang et al., 2011). The data was then refined, correcting 
the mass and charge states of the precursor ions. De novo sequencing was carried out on 
each spot with an error tolerance of 1 Da for parent ions and 0.33 Da for fragment ions. 
Post-translational modifications used when analysing the peak values were: fixed for ICAT 
Light chain (M 227), ICAT Heavy chain (M 236), ICAT Heavy plus GTX (M 562), and GTX (M 
326). The peaks and the de novo sequences were searched against the UniProtKB 2012-11 
Homo Sapiens (Human) Proteome Reference Set (68,079 sequences). 
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3. Results  
All results presented in this project were repeated at least three times. The ABSCIEX 5800 
specification for mass accuracy in the linear mode, which is used to measure proteins, is 500 
ppm with external calibration, this corresponds to a mass accuracy of approximately 20 Da 
for a 40 kDa protein. The mass accuracy specification for measurement of peptide masses in 
reflector mode is 25 ppm external. 
3.1 Mass spectrometry of CK 
Fig. 9 shows representative MALDI spectra of native CK. CK was analyzed in the positive ion 
linear mode.  External calibration was carried out using thioredoxin (M+1, 11674), 
apomyoglobin (M+1, 16952) and apomyoglobin (2M+1, 33903). The measured mass of CK 
from 45 spectra gave a mean of 42,944 ± 24 for the expected 1+ (M+1) ion, although this 
mass was greater than the calibrant masses.  The spectra also contained an approximately 
21 kDa mass corresponding to the 2+ (M+2) ion, and an approximately 86 kDa mass that may 
represent a CK dimer or two CK molecules sharing a proton (2M+1). The protein size was 
also calculated from the average mass of the M+2 ions resulting in 43,012 as the average 
mass. The UniProtKB (www.uniprot.org) search result for rabbit CK (Entry P00563) gives a 
predicted average mass 43,112 Da for the full length sequence, or 42,981 if the N-terminal 
methionine is removed. The measured m/z 42,944 ± 24 therefore suggests the presence of 
the N-terminally processed protein assuming the accuracy of the calibration. The 
nomenclature for peptides used in this thesis, however, assumes the protein contains the N-
terminal methionine, for example the peptide ECVGLQK (residues 253-259) contains Cys-
254. In subsequent experiments CK and its reaction products were analyzed in the same 
batch.  
Fig. 10 shows the MALDI spectrum of a tryptic digest of CK. Arrows indicate ions consistent 
with the predicted masses of the four cys-containing peptides. Appendix B lists the 
predicted masses of all tryptic peptides of CK including peptides resulting from one missed 
cleavage or oxidation of methionine. Table 1 summarizes the predicted masses of the cys-
containing peptides, including allowance for up to two missed tryptic cleavages, and shows 
that all four peptides were detected in the MALDI spectra. Abundant ions at 794.43, 
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1130.55 and 2870.37 (Fig. 10) correspond to peptides containing Cys-254, 146 and 283 
respectively. Fig. 11 shows the Cys-254 ion. A minor peak at 4372.92 corresponds to the 
predicted m/z of the peptide containing Cys-74 in residues 46-86 but the signal to noise 
ratio was low and larger ions such as this generally give weak spectra in CHCA matrix. An ion 
at m/z 950.54 is consistent with the presence of the peptide R.FCVGLLQK resulting from one 
missed cleavage of the Cys-254 tryptic peptide.  
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Figure 9: MALDI-TOF mass spectrometry of CK 
The MALDI spectra of CK in sinapinic acid matrix show the approximately 43 kDa mass of CK 
(arrow). The dotted arrow indicates a mass that could be a 2M+1 or a dimer of CK. The 
asterisk indicates the probable 2+ (M+2) ion of CK. 
 
 
 
 
 
* 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: MALDI-TOF of peptide mass fingerprint of CK 
This mass spectrum was acquired from CK after digestion with trypsin and preparation in 
CHCA matrix. Arrows indicate ions consistent with the cys-containing peptides with zero 
missed cleavage and the dotted arrow is consistent with the Cys-254 peptide with one 
missed cleavage. Asterisks indicate ions that correspond to other predicted tryptic peptides 
of CK whose masses are listed in Appendix B. 
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Figure 11: MALDI-TOF ion corresponding to the predicted FCVGLQK peptide  
The arrow indicates the ion that corresponds to the predicted m/z of the Cys-254 containing 
peptide. The spectrum shows resolution of the isotopic peaks. 
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Cysteine 
residue 
(peptide) 
Missed 
Trypsin 
cleavages 
Predicted 
m/z 
Sequence CK Alkylated 
CK  
Cys-74 
 
(46-86) 
0  
 
 
4373.02 ETPSGFTLDDVIQTGVDNPG 
HPFIMTVGCVAGDEESYTVFK 
4373? - 
 1  
 
 
4616.15 
 
DK.ETPSGFTLDDVIQTGVDN 
PGHPFIMTVGCVAGDEESYTVFK 
- - 
Cys-146 
 
(139-148) 
0  
 
 
1130.54 
 
GYTLPPHCSR 1130  1187  
 1  
 
 
1458.75 
 
SIK.GYTLPPHCSR - - 
 1  
 
 
1472.71 
 
GYTLPPHCSR.GER - - 
Cys-283 
 
(267-292) 
0 
 
  
2870.39 AGHPFMWNEHLGYVLTCPSNLGTGLR 
 
2870  2927  
 1 
 
  
2998.48 K.AGHPFMWNEHLGYVLTCPSNLGTGLR 
 
- 3055 
 1 
 
  
3447.72 
 
AGHPFMWNEHLGYVLTCPSNLGTGLR.GGVHVK - - 
Cys-254 
 
(253-259) 
0 
 
  
794.42 
 
FCVGLQK 794  851  
 1 
 
  
950.52 
 
R.FCVGLQK 950 - 
 1 
 
  
1553.84 
 
FCVGLQK.IEEIFK - - 
Table 1: Masses of cys-containing tryptic peptides of CK and alkylated CK, with 0 or 1 missed 
cleavage. Ticked masses represent peptides which were observed in the MALDI spectra. The 
expected mass accuracy using external calibration from peptide standards on the same 
MALDI plate is 25 ppm or 0.025 per 1000 Da peptide. 
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3.2 Modification of CK 
In subsequent experiments the masses of CK and its tryptic peptides were measured after 
reaction of the protein with GTX, and with iodoacetamide or ICAT reagents that alkylate 
cysteine residues. Table 2 summarizes the expected mass increments, and Table 3 
summarizes the predicted masses of any resulting cys-containing peptides in the tryptic 
digests. The predicted addition for GTX is calculated to be the same as the molecular weight 
of oxidized GTX if GTX disulfide reacts with an accessible cysteine thiol (Fig. 2).   
 
 
Table 2: Expected mass additions for reaction of cysteine residues with IAA, GTX, or Light 
and Heavy ICAT reagents. ICAT masses are shown before or after cleavage of the biotin tag. 
 
 
Cys-containing tryptic 
peptides 
Predicted mass (M+H+) 
Mass (m/z) 
 
Peptide IAA GTX GTX + 
Heavy ICAT 
Light ICAT Heavy ICAT Cleaved 
Light ICAT 
Cleaved 
Heavy ICAT 
794.4 
 
253-259 851.4 1120.8 1356.96 1701.9 1710.9 1021.53 1030.56 
1130.5 
 
139-148 1187.6 1456.9 1693.06 2037.9 2047 1357.63 1366.66 
2870.4 
 
267-292 2927.4 3196.8 3432.96 3777.8 3786.9 3097.53 3106.56 
4373 
 
46-86 4430 4699.4 4935.56 5280.5 5289.5 4600.13 4609.16 
Table 3: Predicted masses of cys-containing peptides after modification of CK with 
IAA, GTX, or Light and Heavy ICAT (before or after cleavage of the biotin tag). 
 
 
Reactant Expected mass addition 
IAA 57 
GTX  326.4 
Light ICAT 907.5 
Heavy ICAT 916.5 
Cleaved Light ICAT 227.13 
Cleaved Heavy ICAT 236.16 
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3.3 Alkylation of CK 
Reaction of CK with iodoacetamide is expected to alkylate accessible cysteine residues, 
resulting in a mass addition of 57 for each alkylated cysteine. The size of alkylated CK was 
43,020 ± 18 Da (Fig. 12) which indicated modification of approximately one cysteine per CK 
molecule. Analysis of the tryptic peptides from alkylated CK (Fig. 13) indicated the presence 
of unmodified and alkylated peptides (Table 1). The tryptic digest of alkylated CK contained 
ions at m/z 851, 1187, and 2927 corresponding to mass additions of 57 to the Cys-254, 146, 
and 283 peptides. An ion at m/z 1130 corresponding to unmodified Cys-254 was also 
present indicating partial reaction of this cysteine. An ion at m/z 3055 is consistent with the 
Cys-283 peptide with one missed cleavage and a 57 Da adduct (2998 + 57). The presence of 
multiple alkylated peptides in the tryptic digest was not consistent with the smaller mass 
addition to the protein (Fig. 12), although one explanation is that some alkylation of 
peptides continued during the tryptic digestion. 
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Figure 12: MALDI-TOF MS of IAA treated CK  
Figure shows the spectra of CK alkylated with IAA. Sample was prepared in sinapinic acid as 
the matrix. The acquired spectra were calibrated using Cal 3 standard. The mean mass was 
43,020 ± 18. 
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Figure 13: MALDI-TOF MS of a tryptic digest of CK alkylated with IAA 
The solid arrows indicate cys-containing peptides with a 57 Da addition. Dotted arrow 
indicates Cys-283 with one missed cleavage that has a 57 Da addition, and the asterisk 
indicates a mass consistent with the unmodified Cys-146 containing peptide. 
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3.4 Reduction and alkylation of CK  
To further examine the accessibility of CK cysteines to alkylation, CK was first treated with 
DTT and then reacted with IAA.  DTT reduces disulfide bonds and therefore facilitates the 
reaction of IAA with cysteine residues. Fig. 14 shows the MALDI spectra of the protein 
product. The result of 10 experimental measurements gave a mean of 43,178 ± 26 Da that is 
consistent with alkylation of three to four cysteines of CK (an addition of about 197 Da). The 
mass fingerprint of the tryptic digest of this sample is shown in Fig. 15. The spectrum 
contains ions at m/z 851, 1187, and 2927 corresponding to the Cys-254, 146, and 283 
peptides each with a mass addition of 57. The spectrum also contains ions at m/z 3055 and 
4673 which are consistent with Cys-283 and 74 with one missed cleavage that have a 57 Da 
addition (2998 + 57 = 3055), (4616 + 57 = 4673). The ion at m/z 1130 corresponds to an 
unreacted Cys-146 peptide. 
 
 
 
 
 
 
 
 
 
Figure 14: MALDI-TOF MS of reduced-alkylated CK 
The reaction products of reduced and alkylated CK in sinapinic acid matrix (arrowhead) 
show a mean of 43,178 ± 26 m/z.   
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: MALDI-TOF MS of tryptic digest of reduced and alkylated CK  
Mass spectrum of reduced-alkylated CK digested with trypsin. Solid arrows indicate the cys-
containing peptides that have an addition of 57 Da. The dotted arrows indicate the cys-
peptides with one missed cleavage that have a 57 Da addition and the asterisk indicates an 
ion consistent with unmodified Cys-146 containing peptide. Detail of the m/z 851.4 ion is 
shown in Fig. 16. 
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Figure 16: MALDI-TOF MS of tryptic digest of reduced-alkylated CK 
Region of the m/z 851.4 ion corresponding to a Cys-254 peptide with a 57 Da addition. 
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3.5 Reaction of CK with GTX  
To examine the effects of GTX on CK, CK was reacted with GTX and analyzed by MALDI MS. 
To determine if the reaction of GTX with CK was time dependent, CK was subjected to 
reaction with GTX for 2, 14, and 24 h at 37 0C. The reaction products are shown in Figs. 17, 
18 and 19. Fig. 17 illustrates the reaction products of CK treated with GTX for 2 h. The 
obtained masses with a mean of 42,843 ± 30 indicated that CK had not reacted with GTX in 2 
h. Fig. 18 shows the reaction products of CK treated with GTX for 14 h. The spectra show the 
mean mass of 43,268 ± 44 which indicates that CK has reacted with GTX. The spectrum for 
the tryptic digest of this sample (Fig. 20) shows a minor ion at m/z 1120  which is consistent 
with Cys-254 with a GTX adduct and also contains an ion at m/z 1162.5 which is consistent 
with oxidized Cys-146 (SO2). An ion corresponding to a GTX adduct of the Cys-283 peptide 
(expected adduct mass 3196.8) was not detected. Fig. 19 shows the reaction products of CK 
and GTX after 24 h. The detected masses have a mean of 43,400 ± 97 indicating that CK has 
a product which is more than the mass of one GTX but less than the mass of two GTX 
molecules. Possible explanations include a GTX adduct plus oxidation of some cysteines at 
24 h. 
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Figure 17: MALDI-TOF mass spectrometry of GTX-treated CK  
The spectra show the reaction products of CK reacted with GTX for 2 h that was prepared in 
sinapinic acid matrix. The acquired spectra show a mean of 42,843 ± 30. 
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Figure 18: MALDI-TOF mass spectrometry of GTX-treated CK 
The spectra show the reaction products of CK reacted with GTX for 14 h. The obtained 
masses show a mean of 43,268 ± 44. 
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Figure 19: MALDI-TOF mass spectrometry of GTX-treated CK  
These spectra show the reaction products of CK that was reacted with GTX for 24 h and then 
prepared in sinapinic acid matrix. The obtained masses show a mean of 43,400 ± 97. 
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Figure 20: MALDI-TOF MS of tryptic digest of GTX-treated CK 
The spectrum above shows CK reacted with GTX for 14 h, then digested with trypsin and 
prepared in CHCA matrix. Arrows indicate the cys-containing peptides. A minor ion at m/z 
1120 is consistent with the Cys-254 that has a 326 Da adduct. The detail of this spectrum in 
the mass range of 794 to 1124 Da is shown in Fig. 21. The asterisks indicate non-cys 
containing peptides which are characteristic of a tryptic digest of CK. The dotted arrow 
shows an ion at m/z 1162.5, which is consistent with oxidized Cys-146 (SO2). 
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Figure 21: MALDI-TOF spectrum of tryptic digest of GTX-treated CK 
Detail of the spectrum from GTX-treated CK after digestion with trypsin.  The boxed ions 
indicate m/z 794 corresponding to the Cys-254 peptide and m/z 1120 which is consistent 
with the Cys-254 peptide with an adduct of 326 Da. 
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 3.5.1 Comparing the tryptic peptides of CK and GTX-treated CK 
Fig. 22 compares the tryptic spectra of CK and GTX-treated CK (14 h reacted). Table 4 
summarizes the tryptic digest of GTX-treated CK that exhibits the peptide fragments present 
in trypsinized CK. 
 
Mass position sequence Trypsinized CK Trypsinized 
GTX-treated CK 
     
759 210-215 DWPDAR        
794 253-259 FCVGLQK       
907 Trypsin autolysis        
1130 139-148 GYTLPPHCSR        
1231 87-96 DLFDPIIQDR       
1530 117-130 GGDDLDPHYVLSSR       
1643 224-236 SFLVWVNEEDHLR       
1785 342-358 LGSSEVEQVQLVVDGVK       
2008 321-341 GTGGVDTAAVGSVFDISNAD R       
2164 Trypsin autolysis        
2870 267-292 AGHPFMWNEHLGYVLTCPSN LGTGLR       
3644 178-209 SMTEQEQQQLIDDHFLFDKPVSPLLLASGMAR       
4373 46-86 ETPSGFTLDDVIQTGVDNPG 
HPFIMTVGCVAGDEESYTVF K 
      
 
Table 4: Theoretical and observed masses of trypsinized CK and GTX-treated CK. Ticked 
masses were present in acquired spectra. Masses at 907 and 2164 due to self-autolysis of 
trypsin were predicted from UniProtKB/Swiss-Prot. 
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Figure 22: MALDI-TOF MS of tryptic digests of CK and GTX-treated CK 
The spectra show untreated CK and GTX-treated CK after digestion with trypsin. The upper 
spectrum illustrates the GTX-treated CK and the lower spectrum illustrates the untreated 
CK. Arrows show cys-containing peptides and the asterisked masses show other peptide 
fragments of CK (Table 4).  
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3.6 Reduction of GTX-treated CK with DTT 
It has been reported that DTT prevents inactivation of CK by GTX either by direct reduction 
of GTX and/or by cleavage of the disulfide bond formed between CK and GTX (Hurne et al., 
2000). Therefore, in this experiment CK was reacted with GTX for 14 h and then treated with 
DTT. According to expectation the MALDI spectrum below shows an ion at m/z 42,946, 
illustrating the release of CK from the GTX adduct. The tryptic digest of this sample is shown 
in Fig. 24. The spectrum shows the m/z 1130 ion corresponding to the Cys-146 peptide but 
ions corresponding to the unreacted Cys-254 or 283 peptides were not detected. The m/z 
1162.5 ion corresponding to oxidized Cys-146 peptide (cysSO2) which was present in the 
spectrum of GTX-treated CK was not detected after reduction with DTT. The minor m/z 1120 
ion corresponding to a GTX adduct of Cys-254 peptide was also not detected. 
 
 
 
 
 
 
 
 
 
 
Figure 23: MALDI-TOF MS of GTX-treated CK reacted with DTT  
MALDI spectrum of GTX-treated CK reacted with DTT. This spectrum shows the mass 42,946. 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: MALDI-TOF MS of tryptic digest of GTX-treated CK reacted with DTT 
The spectrum shows GTX-treated CK reacted with DTT and digested with trypsin. The arrow 
indicates the Cys-146 tryptic peptide. Ions corresponding to the Cys-283 (2870.4) or Cys-254 
(794.4) peptides or the GTX adducts were not detected. Expected non-cys peptides with 1 or 
2 missed cleavages are marked with asterisks. 
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3.7 Alkylation of GTX-treated CK with IAA 
Figs. 12 and 13 showed the alkylation of cysteine residues of CK. To ascertain the 
involvement of sulfhydryls of cysteines in the reaction of CK with GTX, CK was reacted with 
GTX for 14 h and then with IAA for 1 h. The prediction was that cysteines modified by 
reaction with GTX would not be accessible to reaction with IAA although there may be 
alkylation of the free thiol group of GTX in adducted peptides (Fig. 2). Fig. 25 shows the 
MALDI spectra of the protein. The spectra show the mean mass of 43,057 ± 3.6 m/z, which 
is consistent with alkylation of two cysteines of GTX-free CK. This was an unexpected result 
as the predicted product was CK with addition of GTX plus alkylation. The tryptic digest of 
this sample in Fig. 26 shows ions at m/z 1187 and 2927 that are consistent with Cys-146 and 
283 peptides with a mass addition of 57, indicating that these cysteines were not adducted 
by GTX.  The ion at m/z 3055 shown in this spectrum is consistent with the Cys-283 with one 
missed cleavage that has a 57 Da adduct (2998 + 57 = 3055 Da). Ions corresponding to the 
cys-containing peptides with a GTX adduct, or with GTX plus IAA were not detected. 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: MALDI-TOF mass spectrometry of GTX-treated CK reacted with IAA 
The MALDI spectra of alkylated GTX-treated CK in sinapinic acid matrix.  The masses have a 
mean of 43,057 ± 4.   
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Figure 26: MALDI-TOF spectrum of tryptic digest of GTX-treated CK alkylated with IAA 
The spectrum shows the GTX-treated CK reacted with IAA then digested with trypsin and 
prepared in CHCA matrix. Solid arrows indicate the Cys-146 and 283 containing peptides 
with a mass addition of 57.  Dotted arrow indicates the Cys-283 with one missed cleavage 
and a mass addition of 57. The asterisk corresponds to the unmodified Cys-146 peptide.  
 
 
 
 
* 
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3.8 Oxidation of CK with H2O2 
To enable better understanding of the reaction of CK with GTX, CK was also reacted with 
H2O2 as a control. It was predicted that cysteine residues of CK would be oxidized after 
treatment with H2O2 to sulfenic (CH2SO), sulfinic (CH2SO2) or sulfonic (CH2SO3) acids (Table 
5) and/or formation of an internal disulfide bond in CK. CK was subjected to reaction with 
H2O2 at room temperature for 10 min and the reaction was stopped by addition of catalase.  
The MALDI spectra in Fig. 27 show the reaction products with a mean mass of 43,020 ± 9 
m/z which is consistent with the addition of two oxygen molecules to the cysteine residues 
of CK. The tryptic digest of this sample in Fig. 28 shows minor ions at m/z 1162.5 and 1178.5 
corresponding to the Cys-146 peptide with two or three oxygen additions, but an abundant 
ion at 1130.5 was consistent with unmodified Cys-146 peptide. Although there was 
complete loss of the 2870.4 ion corresponding to the Cys-283 peptide (compare the 
spectrum in Fig. 10) products corresponding to cysteine oxidation were not detected. 
Possible explanations are that the oxidized peptides may not ionize well in the MALDI 
source, or that Cys-283 was oxidized to an intramolecular disulfide of CK. The mass of the 
oxidized protein corresponds to a single molecule of CK (Fig. 27), like CK (Fig. 9), suggesting 
that there was not substantial formation of disulfide bonded dimers of CK (expected mass 
approximately 86 kDa).  
 
 
Table 5: Predicted mass change of oxidized cys-containing tryptic peptides by addition of 
one, two, or three oxygen molecules.  
 
 
peptides Mass (m/z) SO SO2 SO3 
253-259 794.4 810.4 826.4 842.4 
139-148 1130.5 1146.5 1162.5 1178.5 
267-292 2870.4 2886.4 2902.4 2918.4 
46-86 4373 4389 4405 4421 
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Figure 27: MALDI-TOF mass spectrometry of H2O2 treated CK  
The spectra above show the reaction products of H2O2 treated CK in sinapinic acid matrix 
(arrowhead). These masses have a mean of 43,020 ± 9 m/z. 
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Figure 28: MALDI-TOF MS of tryptic digest of H2O2 treated CK 
This MALDI spectrum shows the tryptic digest of H2O2 treated CK in CHCA matrix. The 
spectrum contains ions at m/z 1162.5 and 1178.5 corresponding to oxidized Cys-146 peptide 
with two and three oxygen molecules respectively. The m/z 1130 ion corresponds to the 
unmodified Cys-146 containing peptide. The lower small box indicates the mass range of 
723.4 to 1011.5 Da. 
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3.9 ICAT labeling of CK 
In order to ascertain which cysteines of CK are modified by GTX, the ICAT approach was 
used which labels free cysteines. Initially native CK was reacted with Light ICAT reagent as a 
control. The expected mass addition to cysteine residues was 907.5 Da. The MALDI 
spectrum in Fig. 29 shows the masses of the reaction products; a, addition of ICAT to one 
cysteine; b, addition of ICAT to two cysteines; c, addition of ICAT to three cysteines; d, 
addition of ICAT to all four cysteines. Mass additions corresponding to 1-4 added ICAT 
residues were detected unlike the more limited alkylation of CK by IAA.  
A spectrum for a tryptic digest of this sample is shown in Figs. 30 and 31 and contains ions at 
m/z 1701 (low intensity), 2037, and 3777 consistent with the Cys-254, 146, and 283 peptides 
with 907.5 Da mass additions. 
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Figure 29: MALDI-TOF mass spectrum of CK labeled with Light ICAT  
The spectrum shows Light ICAT-labeled CK in sinapinic acid matrix. The biotin tag was not 
cleaved after reaction. The spectrum indicates the presence of CK with 1-4 ICAT residues, 
with greatest abundance of the maximally labeled species.  The labels a, b, c, d indicate 
labeling of 1-4 cysteine residues. Detected masses show 42995 (CK), 43803 (+ 808 Da), 
44816 (+ 1821 Da), 45665 (+2670 Da), 46444(+3449 Da).  
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Figure 30: MALDI-TOF MS of tryptic digest of Light ICAT-labeled CK 
The spectrum shows the Light ICAT-labeled CK digested with trypsin. The biotin tag was not 
cleaved from the ICAT product. Solid arrows indicate potential cys-containing peptides with 
a 907.5 Da mass addition. The dotted arrow indicates unreacted Cys-146.  
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Figure 31: MALDI-TOF MS of Light ICAT-labeled CK before and after desalting and 
concentration 
The MALDI spectra of the tryptic peptides of Light ICAT-labeled CK. Spectrum A shows the 
sample prepared by the dried droplet method (without desalting) and spectrum B shows the 
sample after desalting and concentration using Eppendorf PerfectPure® C-18 Tips. The 
arrows indicate potential masses of cys-containing peptides with a possible Light ICAT 
product.  
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 3.10 ICAT labeling of GTX-treated CK 
To further examine which cysteines of CK were modified, CK was reacted with GTX for 14 h 
and then with Light ICAT reagent for 2 h at 37 0C. Fig. 32 shows the MALDI spectra of this 
sample. The spectra have a mean mass of 43,145 ± 23 m/z, implying that ICAT did not label 
the cysteine residues, but there was apparently some unexpected mass loss as the mean 
was less than that of GTX-treated CK prior to ICAT labelling Fig 18; 43,268 ± 44.  
In order to compare the ICAT labeling of the cys-containing peptides of untreated CK and 
GTX-treated CK, these samples were labeled with Light and Heavy ICAT reagents 
respectively and were then mixed and digested with trypsin followed by cleavage of the 
biotin tag from the ICAT-labeled peptides (see Section 2.2.5). The mass of Light and Heavy 
ICAT after biotin cleavage is 227.13 and 326.16 Da (9 Da difference). Fig. 33 shows a MALDI 
spectrum from this experiment. An ion at m/z 1021 is consistent with the Cys-254 with a 
Light ICAT added. Lack of Heavy ICAT labeling indicates the possible modification of this 
cysteine by GTX. The spectrum contained ions consistent with Light (1357.5767) and Heavy 
(1366.6021) ICAT tags on Cys-146. The m/z 3097 ion in this spectrum is consistent with the 
Cys-283 with a Light ICAT only. Absence of the Heavy ICAT labeling indicates the possible 
modification of this cysteine by GTX. The unlabeled fraction that was washed from the 
avidin cartridge was also analyzed by MALDI (Fig. 37) to detect other possible modified 
peptides. This spectrum contains a very low abundance ion with a low signal to noise at m/z 
1120.66 possibly corresponding to the Cys-254 peptide with a GTX adduct.  
To further examine the peptides modified by GTX, MS/MS was carried out. MS/MS of the 
m/z 1357 predicted Cys-146 peptide ion was consistent with the expected sequence 
(GYTLPPHC(+227.13)SR) (Fig. 38) with a  Light ICAT on the cysteine residue. The other 
primary ions had weaker MS/MS signals that were more difficult to interpret.  
Overall, the results of ICAT analysis indicated that Cys-254 and 283, and possibly Cys-146 
appeared to be modified and less susceptible to ICAT labeling. 
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Figure 32: MALDI-TOF mass spectrometry of Light ICAT-labeled GTX-treated CK  
The spectra above show the products of reaction of Light ICAT reagent with GTX-treated CK. 
The biotin tag was not cleaved from the ICAT product. The mean mass was 43,145 ± 23. 
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Figure 33: ICAT spectra of a trypsin digest of a mixture of Light ICAT-labeled CK plus Heavy 
ICAT-labeled GTX-treated CK 
The MALDI-TOF MS spectrum above shows the Heavy ICAT-labeled GTX-treated CK and the 
Light ICAT-labeled untreated CK that were mixed and digested with trypsin. The m/z 1130 
ion corresponds to the unmodified Cys-146 peptide and the arrows indicate cys-containing 
peptides with the possible ICAT label.  Detail of the masses is shown in Figs. 34, 35, and 36. 
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Figure 34: MALDI-TOF MS of ICAT labeling of Cys-254 peptide 
The spectrum shows a region of the spectrum from Fig. 33. The m/z 1021 ion is consistent 
with Cys-254 peptide with a Light ICAT tag (794 + 227.13 = 1021 Da).  
 
 
 
 
 
 
 
 
Cys-254, 0 missed cleavage  
FCVGLQK 
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Figure 35: MALDI-TOF MS of ICAT labeling of Cys-146 peptide  
The spectrum illustrates a region of the spectrum from Fig. 33 that contains ions consistent 
with a Light (1357.5767) and Heavy (1366.6021) ICAT on Cys-146, with apparent lower 
intensity of the Heavy label. 
 
 
 
 
 
 
 
 
 
Cys-146, 0 missed cleavage 
GYTLPPHCSR 
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Figure 36: MALDI-TOF MS of ICAT labeling of Cys-283 peptide 
The spectrum illustrates a region of the spectrum from Fig. 33, which shows a minor m/z 
3097 ion that is consistent with the Cys-283 with a 227.13 Da adduct corresponding to Light 
ICAT.  
 
 
 
 
 
 
 
 
Cys-283, 0 missed cleavage 
AGHPFMWNEHLGYVLTCPSNLGTGLR 
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Figure 37: MALDI-TOF MS of GTX adduct on Cys-254 peptide 
Figure shows the spectrum corresponding to the unlabeled fraction of ICAT experiment that 
was washed from the avidin cartridge, as explained in Section 2.2.5. This spectrum contains 
a low intensity ion at m/z 1120, which is consistent with the Cys-254 peptide with a possible 
GTX adduct. The peaks were deisotoped using Data Explorer software. 
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Figure 38: The peptide sequence corresponding to the m/z 1357.6 ion  
The arrow indicates the cys-containing peptide sequence of the Cys-146 peptide that has a 
227.13 Da adduct on cys residue corresponding to the Light ICAT reagent. 
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3.11 Alkylation of H2O2 treated CK with IAA 
As previously shown in Section 3.8, exposure of CK to H2O2 was consistent with oxidation of 
Cys-146. It was therefore decided to examine alkylation of CK treated with H2O2. H2O2 
treated CK was reacted with IAA for 1 h. Fig. 39 shows the reaction products of this 
experiment that have a mean mass of 43,032 ± 17. The mass of H2O2 treated CK prior to the 
reaction with IAA was 43,020 ± 9, therefore it seems that the mass addition was less than 
the mass of one IAA, subject to the standard errors in mass accuracy. However, the 
spectrum for the tryptic digest of this sample (Fig. 40) contains an m/z 1187 ion 
corresponding to Cys-146 peptide with a 57 Da addition. The m/z 1130 ion corresponding to 
the unmodified Cys-146 was also present in the spectrum suggesting only partial alkylation. 
Ions at 851.4 or 2927.4 (Table 3) corresponding to alkylation of the Cys-254 or 283 peptides 
were not detected suggesting that these cysteines had been modified by reaction with H2O2.  
 
 
 
 
 
 
 
 
 
Figure 39: MALDI-TOF mass spectrometry of alkylated H2O2 treated CK with IAA 
The spectra above show the H2O2 treated CK reacted with IAA and have the mean of 43,032 
± 17 m/z.  
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Figure 40: MALDI-TOF MS of tryptic digest of H2O2 treated CK reacted with IAA 
The spectrum shows the H2O2 treated CK after alkylation and digesting with trypsin. Arrows 
indicate an m/z 1130 ion corresponding to the Cys-146 peptide and a m/z 1187 ion which is 
consistent with Cys-146 peptide with a mass addition of 57.  
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3.12 Summary of MS of CK 
The results showed that the reaction of CK with GTX was time dependent and after 14 h the 
mass of CK was consistent with addition of one GTX. However, the tryptic digest of GTX-
treated CK showed only a minor m/z 1120 ion consistent with the Cys-254 peptide with a 
GTX adduct. Treatment with DTT resulted in release of protein with the mass of CK.  
The results of ICAT labeling indicated that Cys-254 was modified by exposure to GTX as it 
lost reactivity to ICAT labelling. The minor m/z 1120 ion that was detected in the fraction of 
unlabeled peptides again suggested binding of GTX to this cysteine. Additionally Cys-283 lost 
reactivity to ICAT but an ion corresponding to this cysteine with a possible GTX adduct was 
not detected. Cys-146 was accessible to reaction with ICAT both before and after exposure 
of CK to GTX, but the ratio of Light/Heavy was approximately 0.5. 
Reaction of CK with H2O2 was consistent with addition of two oxygen molecules to CK. A 
tryptic digest of this sample indicated oxidized Cys-146 (SO2 and SO3). Table 6 summarizes 
the masses of tryptic peptides of CK after reaction of the cys-containing peptides with GTX 
and H2O2. 
Samples  Predicted mass 
 
Observed mass 
Cys- 
254 
Cys- 
146 
Cys- 
283 
Cys-  
74 
Cys-  
254 
Cys- 
 146 
Cys- 
283 
Cys- 
 74 
CK 794 1130 
 
2870 4373 794 1130 2870 4373* 
CK + GTX 1120 1456 
 
3196 4699 1120* - - - 
CK + Light ICAT 1021 1357 
 
3097 46000 1021 1357 3097* - 
CK + GTX + 
Heavy ICAT 
Cys + GTX 1120 1456 
 
3196 4699 1120* - - - 
Cys + Heavy ICAT 1030 
 
1366 3106 4609 - 1366 - - 
 
CK + H2O2 
 
 
Oxidized 
Cys 
SO 810 1146 2886 4389 - - - - 
SO2 826 1162 2902 4405 - 1162* - - 
SO3 842 1178 2918 4421 - 1178 - - 
Table 6: Predicted and observed masses of cys-containing tryptic peptides. Asterisks 
indicate ions that have minor intensity. 
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3.13 Morphological effects of GTX on HL-60 cells 
3.13.1 Treatment of HL-60 cells with GTX  
To examine the effects of GTX on HL-60 cells, flasks containing 9x106 cells in 10 mL of 
medium were treated with 2, 10 or 50 µg GTX. Control flasks contained 10 µL added DMSO. 
Morphological changes were examined at 24 h after GTX treatment. Images were captured 
using phase contrast microscopy. Morphological changes were present in 10 and 50 µg GTX-
treated flasks (Fig.41). Some cells showed blebbing. The images at 10x objective (Fig. 42 A) 
show debris around the cells. Trypan blue exclusion (images not shown) showed cell viability 
after 24 h was 89.7% for untreated controls, 91.2% for DMSO control, 59.8 % for 2 µg GTX-
treated, 14.5% for 10 µg GTX-treated and 11.3% for 50 µg GTX-treated cells respectively. 
 
                                                                    
 
Figure 41: Cultured HL-60 cells at 24 h after GTX treatment 
HL-60 cells 24 h after treatment with 2, 10 and 50 µg GTX at 20x magnification. Untreated 
and DMSO treated samples are controls. The arrows indicate cells with blebs. 
 
  
    
 
 
 Untreated                         DMSO                             2 µg GTX                       10 µg GTX                          50 µg GTX 
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Figure 42: Cultured HL-60 cells at 24 h after GTX treatment  
(A) HL-60 cells 24 h after GTX treatment, 10x magnification. The arrows show debris formed 
around the GTX-treated cells. (B) HL-60 cells at 20x magnification. The GTX-treated cells 
show changes in their shapes compared with the untreated cells. 50 µg GTX sample show a 
clump of cells (arrow) which the results of the trypan blue test identified were dead cells.  
 
 
 
 
 
 
                   Untreated                                          10 µg GTX                                                  50 µg GTX 
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3.13.2 ICAT analysis of HL-60 cells exposed to GTX 
3.13.2.1 MALDI MS 
A preliminary examination of ICAT labeling of HL-60 cells was carried out to investigate the 
potential for detection of protein modification by GTX. The proteins of 10 µg GTX-treated 
and untreated HL-60 cells were extracted and labeled with Heavy and Light ICAT reagents 
respectively using the methods described in Section 2.2.5. Although there were major 
change in cell viability at this concentration of GTX it was expected that changes in protein 
modification would be great enough for detection. 
Fig. 43 shows MALDI mass spectrometry of the lCAT labeled samples. The spectrum contains 
potential ICAT pairs of peptides with 9 Da differences. From this preliminary data it is not 
possible to estimate the differences in ion intensity that reflect significant differences in 
Light and Heavy ICAT labeling but Light/Heavy ratio > 2 may reflect modification of cysteine 
after exposure of CK  to GTX. Potential ICAT pairs were 704.3/713.3, 725.4/734.4, 
742.4/751.4, 881.4/890.4, 932.5/941.5, 964.4/973.4, 984.4/993.4, 1006.4/1015.4. 
Additionally other major ions may be cys peptides labeled only with Light ICAT. If Heavy 
ICAT is greater abundance, it is possible that reduced GTX in cells has reacted with protein 
disulfides resulting in adducted proteins with the second cysteine of the disulfide being 
exposed to reaction with ICAT reagent. The MS/MS spectra of ICAT pairs were searched 
using de novo Sequencing Assisted Database Search (Zhang et al., 2011) in PEAKS software 
to find the sequences of the potential ICAT-labeled peptides. The derived sequences for 
most of the potential ICAT pairs contained cys residues (Appendix C) but without ICAT mass 
tags. Further analysis of the MS/MS ions would be necessary to confirm the identity of these 
peptides. 
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Figure 43: MALDI-TOF MS of tryptic digest of a mixture of Light ICAT-labeled untreated HL-
60 cells plus Heavy ICAT-labeled GTX-treated HL-60 cells  
The spectra show the Light and Heavy ICAT-labeled peptides of HL-60 cells. The boxed 
masses correspond to potential ICAT pairs with 9 Da differences. Each ICAT pair has been 
shown with different shaped boxes. 
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4. Discussion 
GTX is an ETP toxin and redox active molecule that can form mixed disulfides with accessible 
thiol groups on target proteins and/or oxidize thiol groups of proteins (Waring et al., 1995). 
In this project, CK from rabbit muscle was used as an experimental model, followed by 
preliminary examination of the effects of GTX on HL-60 cells. The first experimental strategy 
was use of MS to investigate modification of CK after exposure to GTX. This was done by 
analysis of changes in the mass of CK, and by examination of the masses of tryptic digests of 
CK to determine which cysteines were modified and whether mass changes were consistent 
with formation of GTX adducts or oxidation of cysteines. One complicating factor was that 
Srinivasan et al. (2006) found that although ETPs including GTX formed mixed disulfide 
adducts with the protein glutaredoxin, the adducts could not be detected after tryptic 
digestion of the peptides. They suggested that stability of the mixed disulfides was 
dependent on the conformation of the intact protein. 
CK is a non-covalently bound dimer which contains two identical monomers which separate 
as monomers in the mass spectrometer. CK contains four cysteine residues (Cys-283, Cys-
254, Cys-146, and Cys-74) for each of its monomers. Hurne et al. (2000) proposed that GTX 
interaction with CK includes mixed disulfide formation between GTX and Cys-283 residue of 
CK and/or that reaction leads to oxidation of CK.  Schematics for these reactions are shown 
in Figs. 2 and 5.  
The spectra of native CK (Fig. 9) showed the expected 1+ (M+1) ion with a mean of 42,944 ± 
24 Da which was consistent with the theoretical mass of CK when the N-terminal 
methionine is removed. Fig. 10 shows a tryptic digest of CK that contains ions at m/z 794.43, 
1130.55, 2870.37, and m/z 4372.92 that are consistent with the four cys-containing 
peptides (Cys-254, 146, 283, and 74). This spectrum also contains ions (asterisked) that are 
consistent with the non-cys tryptic peptides of CK. Table 1 summarizes the cys-containing 
tryptic peptides that match the predicted masses. 
Mass spectrometry was also used to examine the reactions of CK. IAA is an alkylating agent 
that reacts with accessible cysteine residues to form carbamidomethyl-cysteine with 
consequent mass addition of 57 for each alkylated cysteine (Tables 2 and 3). Cys-containing 
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peptides are usually detected more efficiently by MALDI MS after alkylation. ICAT reagents 
also contain an IAA moiety that can bind to reactive cysteine residues in proteins. Although 
the increase in mass of CK after reaction with IAA (Fig. 12) indicted reaction equivalent to 
one cysteine for each CK molecule, analysis of the tryptic digests indicated reaction with 
Cys-254, 146, and 283. An ion at m/z 1130 corresponding to unmodified Cys-146 was also 
detected, suggesting partial reaction of this cysteine. Alkylation of the multiple cys-
containing peptides may have been due to continuation of alkylation during the tryptic 
digestion. The initial conclusions were that Cys-254 and 283 were more reactive to 
alkylation than Cys-146. 
In a subsequent experiment CK was reduced with DTT and then reacted with IAA. DTT 
reduces disulfide bonds and facilitates reaction of IAA to thiol groups of cysteine residues. 
After reduction, reaction with IAA was consistent with the alkylation of three to four 
cysteines of CK (Fig. 14). A tryptic digest of this sample (Fig. 15) contained Cys-254, 146, and 
283 peptides with a mass addition of 57 Da. An ion at m/z 1130 corresponding to the 
unmodified Cys-146 peptide indicated the partial reaction of this cysteine with IAA.  
ETP fungal toxins such as GTX disrupt cellular functions through reaction with cysteine 
residues of target proteins (Waring et al., 1995). The toxicity of GTX is dependent on its 
disulfide bond (Fig. 1) that is highly reactive and essential for its activity (Srinivasan et al., 
2006). The possibility of formation of a mixed disulfide between GTX and cysteine residues 
of CK was therefore examined. Formation of a single mixed disulfide adduct of GTX with CK 
was predicted to result in a mass addition of 326.4 (Table 2). 
As shown in Fig. 17 CK did not show modification by GTX after 2 h reaction, but after 14 h 
reaction (Fig. 18) there was a mass increase consistent with addition of GTX. Hurne et al. 
(2000) previously showed time-dependent reaction and that 6 h incubation of CK with 0.1 
mM GTX resulted in 80% inactivation of CK.  
However, analysis of the tryptic peptides after reaction of CK with GTX showed only a minor 
ion at m/z 1120 consistent with formation of a mixed disulfide with the Cys-254 peptide 
(Figs. 20, 21). An ion at m/z 1162.5 was consistent with an oxidized Cys-146 (SO2) peptide. 
Ions corresponding to unmodified Cys-146 and 283 peptides were also present in the 
spectrum. One explanation for lack of detection of major GTX-peptide products might be 
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due to poor ionization of such peptides in the MALDI. Alternatively as suggested by 
Srinivasan et al. (2006) the GTX adducts may be unstable in the tryptic digests. Srinivasan et 
al. (2006) showed that at least four of the five cysteines of glutaredoxin were involved in 
inactivation of this enzyme by sporidesmin or GTX and although an adduct was formed it 
could not be detected in the tryptic digests. 
Hurne et al. (2000) reported that treatment of CK that was inactivated by GTX with reducing 
agents such as DTT or glutathione resulted in the restoration of CK activity. The spectrum in 
Fig. 23 indicates that the modification of CK by GTX was reversible after addition of DTT and 
shows the expected 43 kDa mass of CK. In the tryptic digests (Fig. 24) there was no evidence 
of the m/z 1120 ion corresponding to the possible GTX-modified Cys-254 peptide. However, 
although the Cys-146 peptide was detected, other cys-containing peptides were not 
present. The typtic digest of this sample differed from the digest of CK indicating that there 
may have been other modifications. Apparent addition of two oxygens (+ 32) to the Cys-146 
peptide (m/z 1162.5) was detected with GTX. This mass addition was lost after reduction of 
modified CK with DTT. DTT typically reduces cysteine sulfenic but not sulfinic acids, and as 
there is only a single cysteine in the sequence (GYTLPPHCSR) oxidation of other amino acids, 
possibly including histidine (Ji, Zhang, Cheng & Wang, 2009), should be considered.  
To ascertain the involvement of thiol groups in the reaction of CK with GTX, the GTX-treated 
CK was alkylated with IAA. It was expected that cysteines modified by GTX would no longer 
be accessible to alkylation with IAA. The spectra in Fig. 25 show a mean mass of 43,057 ± 4 
Da, which is less than the mass of GTX-treated CK prior to reaction with IAA. It appears that 
m/z 43,057 is consistent with the presence of GTX-free CK with alkylation of two cysteines. 
Srinivasan et al. (2006) have suggested that the loss of cysteine reactivity might be due to 
elimination of sulfur from cysteine adducts, conformational inaccessibility or sulfur 
oxygenation. The tryptic digest of alkylated GTX- treated CK contained ions consistent with 
Cys-146 and 283 peptides with a mass addition of 57 suggesting that these cysteines were 
not extensively modified by reaction with GTX (Fig. 26).  
Modification of CK thiols was also examined using H2O2 that may oxidize cysteines to form 
sulfenic (CH2SO), sulfinic (CH2SO2), or sulfonic (CH2SO3) acids or promote formation of 
disulfide bonds. Sethuraman et al. (2004) using an ICAT application reported that Cys-283, 
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but not Cys-146 was sensitive to oxidation by 1 mM H2O2. The MALDI spectra of CK reacted 
with H2O2 (Fig. 27) indicate a mean mass of 43,020 ± 9 suggesting addition of two oxygen 
molecules. The tryptic digest (Fig. 28) indicated complete loss of the Cys-283 peptide (loss of 
2870.4) without evidence of the expected products of cys oxidation. There was possible 
evidence of the oxidation of Cys-146 from the presence of m/z 1178.5 (SO3) and m/z 1162.5 
(SO2) ions, although the ion corresponding to unmodified Cys-146 peptide was also present 
indicating the partial reaction of this cysteine. 
To further investigate the reactions of CK, ICAT was used to measure the relative abundance 
of cysteines. The ICAT strategy is based on reaction with cysteine thiol groups in proteins, 
followed by mixing the tagged proteins and enzymatic digestion, and subsequent 
quantitative analysis of the ICAT-labeled peptides using mass spectrometry (Turecek, 2002). 
Native CK labeled with Light ICAT reagent (Fig. 29) showed modification of all four cysteines. 
The spectra indicate the presence of CK and additional 1-4 ICAT residues with greatest 
abundance of the maximally labeled species. The tryptic digest (Figs. 30, 31) confirmed ICAT 
labeling of cys-containing peptides, although labeling of Cys-74 was not seen as the mass 
was beyond the range of detection using CHCA matrix. The presence of the unlabeled Cys-
146 in the spectrum suggests only partial labeling of this cysteine. The Cys-74 peptide also 
has a C-terminal lysine which generally gives a weaker MALDI signal than arginine containing 
peptides. The ICAT reagent showed more reactivity with cysteine residues than had been 
detected with IAA. 
In order to examine which cysteines of CK were modified by GTX, the GTX-treated CK was 
also labeled with Light ICAT reagent. As ICAT labels free cysteines, it was predicted that 
cysteines modified by GTX would lose labeling. The spectra shown in Fig. 32 show a mean 
mass of 43,145 ± 23 which indicates that ICAT had not labeled the cysteine residues. 
However, this mass was less than the mass of GTX-treated CK before reacting with ICAT, 
indicating an unexpected mass loss.  
The next experiment was performed to quantify free cysteines in CK and GTX-treated CK in 
the same spectrum. CK exposed to GTX was labeled with Heavy ICAT (9× 13C) and the control 
CK was labeled with Light ICAT (9× 12C). After digestion with trypsin, the trypsinized 
unlabeled peptides were washed from the avidin cartridge and the ICAT-labeled peptides 
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eluted and analyzed in the MALDI mass spectrometer (Figs. 33-36). Hurne et al. (2000) 
suggested that Cys-74, 146 and 254 require denaturation of CK to be accessible for labeling 
by radiolabeled GTX but Cys-283 is reactive without denaturation. Cysteines that were 
unmodified after reaction with GTX should give similar intensity Light and Heavy ICAT ions 
separated by 9 mass units in the spectrum. Loss of Heavy ICAT labeling is expected for 
cysteines that had been modified in the prior reaction of CK with GTX.  
The ICAT analysis (Fig. 33) showed that Cys-254 only had Light ICAT label (Fig. 34) indicating 
modification of this cysteine after reaction with GTX.  
The Cys-146 peptide had both Light (1357.5) and Heavy (1366.6) labels with the predicted 
mass difference of 9 Da (Fig. 35), although the ratio of Light/Heavy was approximately 0.5. 
In addition, an m/z 1130 ion corresponding to unmodified Cys-146 peptide was present in 
the spectrum (Fig. 33) suggesting that Cys-146 peptide remained unmodified by GTX and 
was less reactive with ICAT. The ICAT-labeled peptides corresponding to Cys-146 gave 
relatively intense signals possibly because arginine-terminated peptides ionize well during 
MALDI MS.  
The Cys-283 peptide ion showed only Light label indicating that this cysteine had been 
modified during reaction with GTX. However, ions corresponding to the Cys-283 with a 
possible GTX adduct, or with a GTX plus Heavy ICAT label, were not detected. In addition to 
possible modifications already discussed, formation of an internal disulfide between Cys-283 
and 74 as proposed by Hurne et al. (2000) would result in loss of reactivity with ICAT 
reagents. 
No peptides corresponding to the Cys-74 peptide with Light or Heavy ICAT were detected. 
The larger mass of this peptide is not compatible with analysis using CHCA matrix. Hurne et 
al. (2000) suggested that the intramolecular disulfide bond is formed between Cys-283 and 
Cys-74 in CK, which are in close proximity (Fig. 4) therefore, it is important to know the 
status of Cys-74 peptide.  
These results are reasonably consistent with those obtained by Hurne et al. (2000) using CK 
treated with radiolabeled [35S] GTX. The obtained peptide fragments showed that [35S] GTX 
reacted with Cys-254 and in lesser amounts with Cys-283, possibly due to rapid conversion 
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of Cys-283 adduct to a CK intramolecular disulfide (Fig. 5). There was no evidence of labeled 
Cys-74 or Cys-146. 
My result that Cys-146 was apparently most susceptible to oxidation was not consistent 
with results obtained by Sethuraman et al. (2004) who used ICAT to identify CK thiols 
sensitive to oxidation by H2O2 and showed that Cys-283 but not Cys-146 was oxidant 
sensitive. One difference was that Sethuraman et al. (2004) used capillary high-performance 
liquid chromatography for peptide separation prior to electrospray MS/MS of the tryptic 
ICAT mixtures. A comparison of CK peptides using MALDI and electrospray ionization might 
be useful as same peptides are better suited to detection using one or the other technique.   
A preliminary examination of the use of ICAT to analyze the effects of GTX on HL-60 cells in 
culture was also carried out. HL-60 cells proliferate continuously in liquid suspension culture 
with a doubling time of about 36 to 48 hours. Light ICAT labeling of control cells, and Heavy 
ICAT labeling of GTX-treated cells was done after 24 h incubation with 10 µg/mL GTX. Then 
was substantial cell injury at this time. 
Fig. 43 shows the spectrum of ICAT-labeled HL-60 cell proteins. The MS/MS spectra of 
potential ICAT pairs were analyzed with PEAKS de novo sequencing software to find the 
sequences of the ICAT-labeled peptides. Although potential pairs of ICAT peptides were 
detected in the MALDI MS/MS spectra ICAT tagged sequences were not predicted using 
PEAKS. The results therefore indicate both the potential of ICAT labeling and the need for 
chromatographic separation of peptides before MS/MS. This could be done using either the 
TEMPO MALDI spotter for high performance liquid chromatographic separation of peptides 
prior to MS/MS or by using on-line chromatography of the tryptic peptides into an 
electrospray ionization mass spectrometric. Chromatographic separation of peptides is the 
commonly used strategy for ICAT as many more peptides are detected in sufficient 
abundance for MS/MS based sequence analysis. 
In summary the results of analysis of CK showed that the ICAT strategy was effective for 
detection of cysteine modification, although it was not possible to completely characterize 
of mechanisms of cysteine modification from the MALDI spectra. The potential ICAT pairs 
identified in HL-60 cell spectra can be further studied including quantitative analysis that 
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would provide information about the relative abundance of free thiols and detection of the 
proteins modified by GTX. 
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4.1 Conclusions and future prospects 
In conclusion, the purpose of this project was to develop mass spectrometry methods to 
examine the reactions of GTX with protein cysteines. Reaction of CK with GTX suggested 
mass addition consistent with formation of an adduct although the expected products could 
not be detected in the tryptic digests. Srinivasan et al. (2006) previously suggested that the 
stability of ETP-protein mixed disulfides was dependent on the conformation of the intact 
protein. ICAT appeared to be more effective than IAA for reaction with CK cysteines, and 
was useful for detection of modified cysteines through the loss of reactivity with ICAT 
reagents. Although modification of CK by GTX appeared to be complex change was detected 
using ICAT, and potential ICAT pairs were detected in HL-60 cells exposed to the toxin. There 
is therefore good potential to apply ICAT for detection of proteins whose cysteine residues 
are modified by GTX or other ETPs. Such studies should be useful in probing the cellular 
toxicity of these compounds.  
 
 
 
 
 
 
 
 
 
 
 
  
78 
 
References 
 Applied Biosystems handbook for methods of ICAT reagents. 
Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422, 198-
207. 
 
Ashcroft, A. E. (2003). Protein and peptide identification: the role of mass spectrometry in 
proteomics. Natural Product Reports, 20, 202-2015. 
 
Balibar, C. J., & Walsh, C. T. (2006). Glip, a multimodular nonribosomal peptide synthetase in 
Aspergillus fumigatus, makes the diketopiperazine scaffold of gliotoxin. Biochemistry, 45, 
15029-15038. 
 
Baust, H., Schoke, A., Brey, A., Gern, U., Los, M., Schmid, R. M., Rottinger, E. M., & 
Seufferlein, T. (2003). Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications 
for a role of NF-KB independent mechanisms. Oncogene, 22, 8786-8796.  
 
Bernardo, P. H., Brasch, N., Chai, C. L. L., & Waring, P. (2003). A novel redox mechanism for 
the glutathione-dependent reversible uptake of a fungal toxin in cells. The Journal of 
Biological Chemistry, 47, 46549-46555. 
 
Biswas, S., Chida, A. S., & Rahman, I. (2006). Redox modifications of protein-thiols: Emerging 
rols in cell signaling. Biochemical Pharmocology, 71, 551-564.  
 
Bok, J. W., Chung, D., Balajee, S. A., Marr, K. A., Andes, D., Nielsen, K. F., Frisvad, J. C., Kirby, 
K.A., & Keller, N. P. (2006). Gliz, a transcriptional regulator of gliotoxin biosynthesis, 
contributes to Aspergillus fumigates virulence. Infection and Immunity, 74, 6761-6768. 
 
Cantwell, J. S., Novak, W. R., Wang, P. F., McLeish, M. J., Kenyon, G. L., & Babiitt, P. C. 
(2001). Mutagenesis of two acidic site residues in human muscle creatine kinase: 
implications for the catalytic mechanism. Biochemistry, 40, 3056-3061. 
 
Chai, C. L., Waring, P. (2000). Redox sensitive epidithiodioxopiperazines in biological 
mechanisms of toxicity. Redox Report, 5, 257-264. 
 
Choi, H. S., Shim, J. S. Kim, J. A., Kang, S. W., & Kwon, H. J. (2007). Discovery of gliotoxin as a 
new small molecule targeting thioredoxin redox system. Biochemical and Biophysical 
Research Communications, 359, 523-528.  
 
Cramer, R. A., Gamcsik, M. P., Brooking, R. M., Najvar, L. K., Kirkpatrick, W. R., Patterson, T. 
F., Balibar, C. J., Graybill, J. R., Perfect, J. R., Abraham, S. N., & Steinbach, W.J. (2006). 
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates 
gliotoxin production. Eukaryotic Cell, 5, 972-980.  
 
 
79 
 
Fox, E. M., & Howlett, B. J. (2008). Biosynthetic gene clusters for 
epipolythiodioxopiperazines in filamentous fungi. Mycological Research, 112, 162-169. 
 
Fridrichsons, J., & Mathieson, A. M. (1967). The crystal structure of gliotoxin. Acta Cryst. 23, 
439- 448. 
 
Fu, C., Hu, J., Liu, T., Ago, T., Sadoshima, J., & Li, H. (2008). Quantitative analysis of redox-
sensitive proteome with DIGE and ICAT. Journal of Proteome Research, 7, 3789-3802.  
 
Fukuyama, T., Nakatsuka, S. H., Kishi, Y. (1981). Total synthesis of gliotoxin dehydrogliotoxin 
and hyalodendrin. Tetrahedron (2045-2078). Cambridge, MA., US: Pergamon Press Ltd. 
 
Gardiner, D. M., Waring, P., & Howlett, B. J. (2005). The epipolythiodioxopiperazine (ETP) 
class of fugal toxins: distribution, mode of action, functions and biosynthesis. Microbiology, 
151, 1021-1032.  
 
Grovel, O., Kerzaon, I., Petit, K., Pont, T. R. D., & Pouchus, Y. F. (2006). A new and rapid 
bioassay for the detection of gliotoxin and related epipolythiodioxopiperazines produced by 
fungi. Journal of Microbiological Methods, 66, 286-293. 
 
Hood, B. L., Veenstra.T.D., Conrads.T.P. (2004). Mass spectrometry-based proteomics. 
International Congress Series 1266 (pp. 375-380). Frederick, MD., USA: Elsevier B.V. 
Hou, L. X., & Zhou, J. X. (1996). Creatine Kinase: The characteristics of the enzyme 
regenerated from the thio-methylated creatine kinase reflect a differentiation in function 
between the two reactive thiols. Biochimie, 78, 219-226. 
 
Hsu, J. L., & Chen, S. H. (2005). Recent progress in quantitative proteomics using stable 
isotope labeling, multidimensional liquid chromatography and mass spectrometry. Current 
Proteomics, 2, 287-302.  
Hur, J. M., Yun, H. J., Yang, S. H., Lee, W. Y., Joe, M. H., & Kim, D. (2008). Gliotoxin enhances 
radiotherapy via Inhibition of radiation-induced GADD45a, P38, NFkB activation. Journal of 
Cellular Biochemistry, 104, 2174-2184. 
 
Hurne, A. M., Chais, C.L.L., & Waring, P. (2000). Inactivation of rabbit muscle creatine kinase 
by reversible formation of an internal disulfide bond by the fungal toxin gliotoxin.  The 
Journal of Biological Chemistry. 275, 25202-25206. 
 
Ji, J. A., Zhang, B., Cheng, W., Wang, Y. J., (2009). Methionine, tryptophan, and histidine 
oxidation in a model protein, PTH: mechanisms and stabilization. Journal of Pharmaceutical 
Sciences, 98, 4485-4500. 
 
Jones, R. W, & Hancock, J. G. (1988). Mechanism of gliotoxin action and factors mediating 
gliotoxin sensitivity. Journal of General Microbiology, 134, 2067-2075. 
 
Jordan, T. W., & Cordiner, S. J. (1987). Fungal epipolythiodioxopiperazine toxins have 
therapeutic potentioal and roles in disease. Trends in Pharmacological Sciences, 8, 144-149. 
80 
 
 
Jordan, T. W., & Pedersen, J. S. (1986). Sporidesmin and Gliotoxin Induce Cell Detachment 
and Perturb Microfilament Structure in Cultured Liver Cells. J. Cell Sci, 85, 33-46. 
 
Lin, K. T., Xue, J. Y., Lin, M. C., Spokas, E. G., Sun, F. F., & Wong, P. Y. k. (1988). Peroxynitrite 
induces apoptosis of HL-60 cells byactivation of a caspase-3 family protease. Am J Physiol 
Cell Physiol 274, C855-C860. 
 
Mann, M., & Kelleher, N. L. (2008). Precision proteomics: The case for high resolution and 
high mass accuracy. Proc Natl Acad Sci U S A, 1-7. 
 
Miller, P.A., Milstrey, K.P., &Trown, P.W. (1968). Specific inhibition of viral ribonucleic acid 
replication by Gliotoxin. Science, 159, 431-432. 
 
Mullbacher, A., & Eichner, R. D. (1984). Immunosuppression in vitro by a metabolite of a 
human pathogenic fungus. Proc Natl Acad Sci U S A, 81, 3835-3837.  
 
Munday, R. (1989). Toxicity of thiols and disulphides: involvement of free-radical species. 
Free Radical Biology and Medicine, 7, 659-673.   
 
Orr, J.G., Leel, V., Cameron, G.A., Marek, C.J., Haughton, E.L., Elrick, L.J., Trim, J.E., 
Hawksworth, G.M., Halestrap, A.P., & Wright, M.C. (2004). Mechanism of action of the 
antifibrogenic compound gliotoxin in rat liver cells.  Hepatology, 40, 232–242. 
 
Page, M. J., Griffiths, T. A.M., Bleackley, M.R., & MacGillivray, R. T. A. (2006) Proteomics: 
applications relevant to transfusion medicine. Transfusion Medicine Reviews, 20, 63-74. 
 
Pahl, H. L., Krau, B. B., Schulze-Osthoff, K., Decker, T., Traenckner, E. B. M., Vogt, M., Myers, 
C., Parks. T., Warring. P., Mühlbacher. A., Czernilofsky, A. P., & Baeuerle, P. A. (1996). The 
immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-
kB. J Exp Med. 183, 1829–1840. 
 
Pan, S., Aebersold, R., Chen, R., Rush, J., Goodlett, D.R., Mcintosh, M. W., Zhang, J., & 
Brentnall, T. A. (2009). Mass spectrometry based targeted protein quantification: methods 
and applications. Journal of Proteome Research, 8, 787-797. 
 
Price, N.C., Hunter, M.G. (1976). Non-identical behaviour of the subunits of rabbit muscle 
creatine kinas. Biochimica et Biophysica Acta (BBA)-Enzymology, 445, 364-376. 
 
Rao. J. K. M., Bujacz, G., & Wlodawer, A. (1998). Crystal structure of rabbit muscle creatine 
kinase. FEBS Letters, 439, 133-137.  
 
Reeves, E. P., Murphy, T., Daly, P., & Kavanagh, K. (2004). Amphotericin B enhances the 
synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary 
pathogen Aspergiluus fumigates. Journal of Medical Microbiology, 53, 719-725. 
 
81 
 
Rementeria, A., Molina, N. L., Ludwig, A., Vivanco, A. B., Bikandi, J., Poton, J., & Garaizar, J. 
(2005). Genes and molecules involved in Aspergillus fumigates virulence. Rev Iberoam Micol, 
22, 1-23. 
 
Rezanka, T., Sobotka, M., Spizek. J., & Sigler, K. (2006). Pharmacologically active sulfur- 
containing compounds. Anti-Infective Agents Medicinal Chemistry, 5, 187-224.  
 
Schrettl, M., Carberry, S., Kavanagh, K., Haas, H., Jones, G.W., O'Brien, J., Nolan, A., 
Stephens, J., Fenelon, O., & Doyle, S. (2010). Self-protection against gliotoxin--a component 
of the gliotoxin biosynthetic cluster, GliT, completely protects Aspergillus fumigates against 
exogenous gliotoxin. PLoS Pathog. 6, 1-15. 
 
Sethuraman, M., McCombs, M. E., Heibeck, T., Costellos, C. E., & Cohen, R. A. (2004). 
Isotope-coded affinity tag approach to indentify and quantify oxidant-sensitive protein 
thiols. Molecular and Cellular Proteomics, 3, 273-278.  
 
Siepen, J. A., Keevil, E. J., Knight, D., & Hubbard, S. J. (2007). Prediction of missed cleavage 
sited in tryptic peptides aids protein identification in proteomics. Journal of Proteome 
Research, 6, 399-408. 
 
Srinivasan, U., Bala, S., Jao, S. C., Starke, D. W., Jordan, T. W., & Mieyal, J.J. (2006). Selective 
inactivation of glutaredoxin by sporidesmin and other epidithiopiperazinediones. 
Biochemistry, 45, 8978-8987. 
 
Stack, D., Neville, C., & Doyle, S. (2007).Nonribosomal peptide synthesis in Aspergillus 
fumigatus. Microbiology, 153, 1297-1306.  
 
Stanzani, M., Orciuolo, E., Lewis, R., Kontoyannis, D. P., Martins, S. L. R., John, L. S. S., & 
Komanduri, K. V. (2005). Aspergillus fumigauts suppresses the human cellular immune 
response via gliotoxin-mediated apoptosis of monocytes. Blood, 105, 2258-2265. 
 
Turecek, F. (2002). Mass spectrometry in coupling with affinity capture-release and isotope-
coded affinity tags for quantitative protein analysis. Journal of Mass Spectrometry. 37, 1-14.  
 
Vanlaere, E., Segeant, K., Dawyndt, P., Kallow, W., Erhard, M., Sutton, H., Dare, D.,Devreese, 
B., Samyn, B., & Vandamme, P. (2008). Matrix-assisted laser desorption-time-of-flight mass 
spectrometry of intact cells allows rapid identification of Burkholdera cepacia complex. 
Journal of Microbiological Methods, 75, 279-286. 
 
Waring, P., Eichner, R. D., Mullbacher, A., & Sjaarda, A. (1988). Gliotoxin induces apoptosis 
in macrophages unrelated to its antiphagocytic properties. The Journal of Biological 
Chemistry, 263, 18493-18499. 
 
Waring, P., Eichner, R. D., &Mullbacher, A. (1988). The chemistry and biology of the 
immunomodulating agent gliotoxin and related epipolythiodioxopiperazines. Medical 
Research Review, 8, 499-524.  
 
82 
 
Waring, P., Sjaarda, A., & Lin, Q. H. (1995). Gliotoxin inactivates alcohol dehydrogenase by 
either covalent modification or free radical damage mediated by redox cycling. Biochemical 
Pharmacology, 47, 1195-1201. 
 
Wu, C.L., Li, Y. H., Lin, H. C., Yeh, Y. H., Yan, H. Y., Hsiao, C. D., Hui, C. F. & Wu, J. L. (2011). 
Activity and function of rabbit muscle-specific creatine kinase at low temperature by 
mutation at gly268 to asn268. Comparative Biochemistry and Physiology, 158. 189-198. 
 
Yamada, A., Kataoka, T., & Nagai, K. (2000). The Fungal metabolite gliotoxin: 
immunosuppressive activity on CTL-mediated cytotoxicity. Immunology Letters, 71, 27-32.  
Zhang, J., Xin, L., Shan, B., Chen, W., Xie, M., Yuen, D., Zhang, W., Zhang, Z., Lajoie, G., & Ma, 
B. (2011). PEAKS DB: de novo sequencing assisted database search for sensitive and accurate 
peptide itdentification.  Molecular & Cellular Proteomics 10.1074/mcp.M111.010587. 
 Zhao, T. J., Yan, Y. B., Liu, Y., & Zhou, H. M. (2007). The generation of the oxidized form of 
cratine kinase is a negative regulation on muscle creatine kinase. Journal of Biological 
Chemistry, 283, 12022-12029. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
Appendix A. Exclusion list for MALDI TOF/TOF MS/MS 
Mass (Da) Tolerance 
2465.19 0.03 
861.60 0.10 
877.000 0.10 
906.505 0.03 
1020.503 0.03 
1153.574 0.03 
1175.523 0.03 
1433.721 0.03 
1493.599 0.03 
1676.777 0.03 
1774.851 0.03 
2163.057 0.03 
2193.003 0.03 
2193.995 0.03 
2273.160 0.03 
2289.155 0.03 
2305.150 0.03 
2514.339 0.03 
2550.233 0.03 
2552.249 0.03 
2612.181 0.03 
2613.350 0.03 
3211.475 0.03 
3227.470 0.03 
805.417 0.03 
659.384 0.03 
 
These ions which are ubiquitously present in all spectra include matrix ions and 
autodigestion products of trypsin. 
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Appendix B. Predicted tryptic peptides of creatine kinase. 
 
 
 
 
 
 
PeptideMass 
The entered protein is: P00563 
The selected enzyme is: Trypsin  
Maximum number of missed cleavages (MC): 1  
All cysteines in reduced form.  
Methionines have been oxidized to form methionine sulfoxide (MSO).  
Using monoisotopic masses of the occurring amino acid residues and giving peptide masses as 
[M+H]+.  
 
You have selected KCRM_RABIT (P00563) from UniProtKB/Swiss-Prot: 
Creatine kinase M-type (EC 2.7.3.2) (Creatine kinase M chain) (M-CK) 
Chain Creatine kinase M-type at positions 1 - 381 [Theoretical pI: 6.63 / Mw (average mass): 43112.06 / Mw 
(monoisotopic mass): 43084.84]  
mass position #MC artif.modification(s)  modifications  peptide sequence 
5585.6402 46-96 1 MSO: 70 5601.6351 
 
 
 
 
ETPSGFTLDDVIQTGVDNPG HPFIMTVGCVAGDEESYTVF 
KDLFDPIIQDR 
4616.1483 44-86 1 MSO: 70 4632.1432 
 
 
 
 
DKETPSGFTLDDVIQTGVDN PGHPFIMTVGCVAGDEESYT VFK 
4385.1328 
178-
215 
1 
MSO: 179, 
207 
4417.1227 
 
 
 
 
SMTEQEQQQLIDDHFLFDKP VSPLLLASGMARDWPDAR 
4373.0264 46-86 0 MSO: 70 4389.0213 
 
 
 
 
ETPSGFTLDDVIQTGVDNPG HPFIMTVGCVAGDEESYTVF K 
4309.1671 
173-
209 
1 
MSO: 179, 
207 
4341.1569 
 
 
 
 
YYPLKSMTEQEQQQLIDDHF LFDKPVSPLLLASGMAR 
3775.8984 
321-
358 
1 
 
 
 
 
 
 
GTGGVDTAAVGSVFDISNAD RLGSSEVEQVQLVVDGVK 
3644.8087 
178-
209 
0 
MSO: 179, 
207 
3676.7985 
 
 
 
 
SMTEQEQQQLIDDHFLFDKP VSPLLLASGMAR 
3447.7201 
267-
298 
1 MSO: 272 3463.7150 
 
 
 
 
AGHPFMWNEHLGYVLTCPSN LGTGLRGGVHVK 
2998.4814 
266-
292 
1 MSO: 272 3014.4763 
 
 
 
 
KAGHPFMWNEHLGYVLTCPS NLGTGLR 
2870.3864 267- 0 MSO: 272 2886.3814 
 
 AGHPFMWNEHLGYVLTCPSN LGTGLR 
85 
 
292  
 
2646.3728 
342-
365 
1 
MSO: 360, 
363 
2678.3626 
 
 
 
 
LGSSEVEQVQLVVDGVKLMV EMEK 
2608.2691 
216-
236 
1 
 
 
 
 
 
 
GIWHNDNKSFLVWVNEEDHL R 
2595.2433 
108-
130 
1 
 
 
 
 
 
 
TDLNHENLKGGDDLDPHYVL SSR 
2331.1801 
224-
242 
1 MSO: 240 2347.1750 
 
 
 
 
SFLVWVNEEDHLRVISMEK 
2199.1192 87-105 1 
 
 
 
 
 
 
DLFDPIIQDRHGGFKPTDK 
2165.0581 
320-
341 
1 
 
 
 
 
 
 
RGTGGVDTAAVGSVFDISNA DR 
2028.9079 16-32 1 MSO: 30 2044.9029 
 
 
 
 
SEEEYPDLSKHNNHMAK 
2008.9570 
321-
341 
0 
 
 
 
 
 
 
GTGGVDTAAVGSVFDISNAD R 
1935.0433 
153-
170 
1 
 
 
 
 
 
 
AVEKLSVEALNSLTGEFK 
1785.9592 
342-
358 
0 
 
 
 
 
 
 
LGSSEVEQVQLVVDGVK 
1785.8878 
117-
132 
1 
 
 
 
 
 
 
GGDDLDPHYVLSSRVR 
1780.9163 26-40 1 MSO: 30 1796.9112 
 
 
 
 
HNNHMAKVLTPDLYK 
1723.7935 
210-
223 
1 
 
 
 
 
 
 
DWPDARGIWHNDNK 
1714.8170 12-25 1 
 
 
 
 
 
 
LNYKSEEEYPDLSK 
1692.9166 
157-
172 
1 
 
 
 
 
 
 
LSVEALNSLTGEFKGK 
1672.8574 
367-
381 
1 MSO: 376 1688.8523 
 
 
 
 
LEKGQSIDDMIPAQK 
1643.8176 
224-
236 
0 
 
 
 
 
 
 
SFLVWVNEEDHLR 
1553.8396 
253-
265 
1 
 
 
 
 
 
 
FCVGLQKIEEIFK 
1530.7183 
117-
130 
0 
 
 
 
 
 
 
GGDDLDPHYVLSSR 
1507.8002 
157-
170 
0 
 
 
 
 
 
 
LSVEALNSLTGEFK 
1472.7063 
139-
151 
1 
 
 
 
 
 
 
GYTLPPHCSRGER 
1458.7522 
136-
148 
1 
 
 
 
 
 
 
SIKGYTLPPHCSR 
1348.6968 
106-
116 
1 
 
 
 
 
 
 
HKTDLNHENLK 
1336.6466 1-11 1 MSO: 1 1352.6416 
 
 
 
 
MPFGNTHNKYK 
1302.6358 
370-
381 
0 MSO: 376 1318.6307 
 
 
 
 
GQSIDDMIPAQK 
86 
 
1269.6950 
305-
314 
1 
 
 
 
 
 
 
HPKFEEILTR 
1251.6592 97-107 1 
 
 
 
 
 
 
HGGFKPTDKHK 
1245.7426 
293-
304 
1 
 
 
 
 
 
 
GGVHVKLAHLSK 
1231.6317 87-96 0 
 
 
 
 
 
 
DLFDPIIQDR 
1196.5317 16-25 0 
 
 
 
 
 
 
SEEEYPDLSK 
1193.6017 
237-
247 
1 
MSO: 240, 
246 
1225.5915 
 
 
 
 
VISMEKGGNMK 
1176.6735 
308-
316 
1 
 
 
 
 
 
 
FEEILTRLR 
1130.5411 
139-
148 
0 
 
 
 
 
 
 
GYTLPPHCSR 
1083.5429 
108-
116 
0 
 
 
 
 
 
 
TDLNHENLK 
1076.6350 33-41 1 
 
 
 
 
 
 
VLTPDLYKK 
1045.4884 1-9 0 MSO: 1 1061.4833 
 
 
 
 
MPFGNTHNK 
1037.5196 
243-
251 
1 MSO: 246 1053.5146 
 
 
 
 
GGNMKEVFR 
1030.6156 
299-
307 
1 
 
 
 
 
 
 
LAHLSKHPK 
1007.5264 
359-
366 
1 
MSO: 360, 
363 
1039.5162 
 
 
 
 
LMVEMEKK 
986.5054 97-105 0 
 
 
 
 
 
 
HGGFKPTDK 
983.4693 
216-
223 
0 
 
 
 
 
 
 
GIWHNDNK 
950.5240 
252-
259 
1 
 
 
 
 
 
 
RFCVGLQK 
948.5400 33-40 0 
 
 
 
 
 
 
VLTPDLYK 
907.4883 
308-
314 
0 
 
 
 
 
 
 
FEEILTR 
906.5295 
260-
266 
1 
 
 
 
 
 
 
IEEIFKK 
879.4314 
359-
365 
0 
MSO: 360, 
363 
911.4212 
 
 
 
 
LMVEMEK 
868.4927 
171-
177 
1 
 
 
 
 
 
 
GKYYPLK 
851.3941 26-32 0 MSO: 30 867.3890 
 
 
 
 
HNNHMAK 
828.4614 10-15 1 
 
 
 
 
 
 
YKLNYK 
794.4229 
253-
259 
0 
 
 
 
 
 
 
FCVGLQK 
778.4345 260- 0   IEEIFK 
87 
 
265  
 
 
 
759.3420 
210-
215 
0 
 
 
 
 
 
 
DWPDAR 
706.3995 
248-
252 
1 
 
 
 
 
 
 
EVFRR 
706.3804 
237-
242 
0 MSO: 240 722.3753 
 
 
 
 
VISMEK 
683.3763 
173-
177 
0 
 
 
 
 
 
 
YYPLK 
668.4090 
299-
304 
0 
 
 
 
 
 
 
LAHLSK 
661.3991 
133-
138 
1 
 
 
 
 
 
 
TGRSIK 
657.4406 
315-
319 
1 
 
 
 
 
 
 
LRLQK 
602.3620 
152-
156 
1 
 
 
 
 
 
 
RAVEK 
596.3514 
293-
298 
0 
 
 
 
 
 
 
GGVHVK 
588.3576 
131-
135 
1 
 
 
 
 
 
 
VRTGR 
550.2983 
248-
251 
0 
 
 
 
 
 
 
EVFR 
544.3565 
317-
320 
1 
 
 
 
 
 
 
LQKR 
537.3031 12-15 0 
 
 
 
 
 
 
LNYK 
531.3249 42-45 1 
 
 
 
 
 
 
LRDK 
517.3344 
366-
369 
1 
 
 
 
 
 
 
KLEK 
517.2841 
149-
152 
1 
 
 
 
 
 
 
GERR 
506.2391 
243-
247 
0 MSO: 246 522.2340 
 
 
 
 
GGNMK 
446.2609 
153-
156 
0 
 
 
 
 
 
 
AVEK 
416.2980 41-43 1 
 
 
 
 
 
 
KLR 
389.2394 
367-
369 
0 
 
 
 
 
 
 
LEK 
388.2554 
317-
319 
0 
 
 
 
 
 
 
LQK 
381.2245 
305-
307 
0 
 
 
 
 
 
 
HPK 
361.1830 
149-
151 
0 
 
 
 
 
 
 
GER 
347.2289 
136-
138 
0 
 
 
 
 
 
 
SIK 
333.1881 
133-
135 
0 
 
 
 
 
 
 
TGR 
88 
 
310.1761 10-11 0 
 
 
 
 
 
 
YK 
288.2030 42-43 0 
 
 
 
 
 
 
LR 
288.2030 
315-
316 
0 
 
 
 
 
 
 
LR 
284.1717 
106-
107 
0 
 
 
 
 
 
 
HK 
274.1873 
131-
132 
0 
 
 
 
 
 
 
VR 
262.1397 44-45 0 
 
 
 
 
 
 
DK 
204.1342 
171-
172 
0 
 
 
 
 
 
 
GK 
175.1189 
152-
152 
0 
 
 
 
 
 
 
R 
175.1189 
252-
252 
0 
 
 
 
 
 
 
R 
175.1189 
320-
320 
0 
 
 
 
 
 
 
R 
147.1128 41-41 0 
 
 
 
 
 
 
K 
147.1128 
266-
266 
0 
 
 
 
 
 
 
K 
147.1128 
366-
366 
0 
 
 
 
 
 
 
K 
100.0% of sequence covered (you may modify the input parameters to display also peptides < 0 Da or > 100000000000 Da):  
        10         20         30         40         50         60  
MPFGNTHNKY KLNYKSEEEY PDLSKHNNHM AKVLTPDLYK KLRDKETPSG FTLDDVIQTG  
 
        70         80         90        100        110        120  
VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGF KPTDKHKTDL NHENLKGGDD  
 
       130        140        150        160        170        180  
LDPHYVLSSR VRTGRSIKGY TLPPHCSRGE RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT  
 
       190        200        210        220        230        240  
EQEQQQLIDD HFLFDKPVSP LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM  
 
       250        260        270        280        290        300  
EKGGNMKEVF RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA  
 
       310        320        330        340        350        360  
HLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GSVFDISNAD RLGSSEVEQV QLVVDGVKLM  
 
       370        380  
VEMEKKLEKG QSIDDMIPAQ K  
 
 
 
 
89 
 
Appendix C. PEAKS analysis of ICAT spectra. 
The peptide sequences for HL-60 ICAT pairs. These figures show the peptide sequences of 
751.4, 725.4, 734.4, 890.4, and 1018.4 ions. 
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User                   : =/B> 
Email                  :  
Search title           :  
Database               : NCBInrEukaryote 23022011 (2385481 sequences; =81413870 residues) 
Taxonomy               : Eukaryota (eucaryotes) (1305516 =equences) 
Timestamp              : 29 Jun 2012 at 04:06:04 GMT 
Enzyme                 : Trypsin 
Variable modifications : Oxidation (M) 
Mass values            : Monoisotopic 
Protein Mass           : Unrestricted 
Peptide Mass Tolerance : ± 0.5 Da 
Fragment Mass Tolerance: ± 0.5 Da 
Max Missed Cleavages   : 0 
Instrument type        : MALDI-TOF-TOF 
Number of queries      : 1180 
 
  
Select Summary Report 
=INPUT value=MIS type=hidden name=SEARCH>                    =INPUT value=OFF type=hidden name=OVERVIEW>  =INPUT 
value="Eukaryota (eucaryotes)" type=hidden name=TAXONOMY>       
     All =ueries     Unassigned =    Below =omology threshold     Below =dentity threshold  
 
Protein =its           : gi|125307  RecName: Full=Creatine kinase =-type; AltName: Full=Creatine kinase M chain; AltName: =ull=M-CK
  gi|125304  RecName: Full=Creatine kinase =-type; AltName: Full=Creatine kinase M chain; AltName: =ull=M-CK
  gi|125310  RecName: Full=Creatine kinase =-type; AltName: Full=Creatine kinase M chain; AltName: Full=M-CK; =ltName: Full=NU-2 protein
  gi|125293  RecName: Full=Creatine kinase =-type; AltName: Full=B-CK; AltName: Full=Creatine kinase B =hain
  gi|3183536 RecName: Full=Creatine kinase =-type, mitochondrial; AltName: Full=Basic-type mitochondrial creatine =inase; Short=Mib-CK; AltName: Full=Sarcomeric mitochondrial =reatine kinase; Short=S
../data/20120629/F107200.dat
 Format As  Select Summary (protein hits)  Help 
 Significance threshold p<  Max. number of hits  AUTO  
 Standard scoring  MudPIT scoring  Ions score or expect cut-off  Show sub-sets  0
 Show pop-ups  Suppress pop-ups    scoredown Require bold red   
Monoisotopic 0.5 0.5 ../data/20120629/F107200.dat
Re-Search
1.    gi|125307    Mass: 43=85    Score: 1106   Ma=ches: 263(101)  Sequences: 20(10) &n=sp;emPAI: 2.40
 RecName: Full=Creatine kinase M-type; AltName: Full=Creatine kinase M chain; AltName: =ull=M-CK
      Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Unique  Peptide
 113  759.3526  758.3453  758.3347  0.0106 0  36  0.4 1       R.DWPDAR.G
 149  778.4458  777.4385  777.4272  0.0113 0  25  4.4 1       K.IEEIFK.K 147 148
 175  794.4398  793.4325  793.4156  0.0169 0  28  1.8 1  U    R.FCVGLQK.I 163 164 165 167 169 171 172 178 179
 450  879.4307  878.4235  878.4241  -0.0007 0  20  12 1       K.LMVEMEK.K 453
 515  907.4846  906.4773  906.4811  -0.0037 0  37  0.22 1  U    K.FEEILTR.L 516 517 519 520 521 523 525 526 530 531 532 533 536 538 540 543 545
 557  914.4544  913.4471  913.4406  0.0065 0  27  2.4 1       M.PFGNTHNK.Y 561 562
 570  948.5413  947.5340  947.5328  0.0013 0  20  12 1  U    K.VLTPDLYK.K 571 574
 607  983.4736  982.4663  982.4621  0.0042 0  43  0.047 1       R.GIWHNDNK.S 608 609 610 611
 612  986.5097  985.5024  985.4981  0.0043 0  72  6.1e-005 1  U    R.HGGFKPTDK.H 613 614 615
 645  1083.5530  1082.5457  1082.5356  0.0101 0  30  0.86 1       K.TDLNHENLK.G 644
 671  1130.5419  1129.5346  1129.5339  0.0007 0  37  0.2 1  U    K.GYTLPPHCSR.G 672 673 676 677 678 679 680 681 683 687 691 694
 729  1196.5387  1195.5314  1195.5244  0.0070 0  51  0.0072 1  U    K.SEEEYPDLSK.H 728 730 731
 749  1231.6428  1230.6355  1230.6245  0.0111 0  67  0.0002 1  U    K.DLFDPIIQDR.H 744 745 746 747 748 750 751 752 753 754 755 756 757 758 759 760 761 762 764 765 766 767 768 769 770 771 772 773 774 775 777 778
 824  1302.6368  1301.6296  1301.6285  0.0010 0  72  5.9e-005 1  U    K.GQSIDDMIPAQK.- 821 825 827
 828  1318.6257  1317.6185  1317.6235  -0.0050 0  (21) 7 1  U    K.GQSIDDMIPAQK.-
 886  1530.7216  1529.7143  1529.7110  0.0032 0  89  7.9e-007 1  U    K.GGDDLDPHYVLSSR.V 885 887 888 889 890 891 892 893 894 895 896 897 898 899 900 902 903 904 905 906 907 908 909 910 911 912 913 914 916 917 918 920 921
 954  1643.8378  1642.8305  1642.8103  0.0201 0  74  2.1e-005 1       K.SFLVWVNEEDHLR.V 951 952 953 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 975 979 980 981
 1027  1785.9600  1784.9527  1784.9520  0.0007 0  99  6.3e-008 1  U    R.LGSSEVEQVQLVVDGVK.L <= onmouseover="if (!browser_EXCLUDE) activateEl('Q1028', event)" onmouseout=clearEl() =ref="http://mascot.vuw.ac.nz/mascot/cgi/peptide_view.pl?file=../data=20120629/F107200.dat&query=1028&hit=1&index=gi%7c12530=&px=1&section=5&ave_thresh=43&_ignoreionsscorebelo==0&report=0&_sigthreshold=0.05&_msresflags=1025&=msresflags2=2&percolate=
 1097  2008.9678  2007.9605  2007.9498  0.0107 0  157  8.7e-014 1  U    R.GTGGVDTAAVGSVFDISNADR.L <=T>1095 1096 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118
 1180  3644.8718  3643.8646  3643.8014  0.0631 0  13  7.1 1  U    K.SMTEQEQQQLIDDHFLFDKPVSPLLLASGMAR.D<=TT> 1179
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2.    gi|125304    Mass: 43=01    Score: 168    =B>Matches: 15(2)  Sequences: 6(1) &n=sp;emPAI: 0.11
 RecName: Full=Creatine kinase M-type; AltName: Full=Creatine kinase M chain; AltName: =ull=M-CK
      Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Unique  Peptide
 113  759.3526  758.3453  758.3347  0.0106 0  36  0.4 1       R.DWPDAR.G
 149  778.4458  777.4385  777.4272  0.0113 0  25  4.4 1       K.IEEIFK.K 147 148
 450  879.4307  878.4235  878.4241  -0.0007 0  20  12 1       K.LMVEMEK.K 453
 607  983.4736  982.4663  982.4621  0.0042 0  43  0.047 1       R.GIWHNDNK.T 608 609 610 611
 645  1083.5530  1082.5457  1082.5356  0.0101 0  30  0.86 1       R.TDLNHENLK.G 644
 1180  3644.8718  3643.8646  3643.8014  0.0631 0  13  7.1 1  U    K.AMTEQEQQQLIDDHFLFDKPVSPLLLASGMAR.D<=TT> 1179
3.    gi|125310    Mass: 42=47    Score: 153    =B>Matches: 35(11)  Sequences: 4(1) &=bsp;emPAI: 0.23
 RecName: Full=Creatine kinase M-type; AltName: Full=Creatine kinase M chain; AltName: Full=M-CK; AltName: =ull=NU-2 protein
      Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Unique  Peptide
 450  879.4307  878.4235  878.4241  -0.0007 0  20  12 1       K.LMVEMEK.R 453
 557  914.4544  913.4471  913.4406  0.0065 0  27  2.4 1       M.PFGNTHNK.W 561 562
 609  983.4780  982.4708  982.4621  0.0087 0  31  0.83 2       R.GIWHNNDK.S 607 608 610 611
 954  1643.8378  1642.8305  1642.8103  0.0201 0  74  2.1e-005 1       K.SFLVWVNEEDHLR.V 951 952 953 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 975 979 980 981
4.    gi|125293    Mass: 42=44    Score: 138    =B>Matches: 12(3)  Sequences: 4(2) &n=sp;emPAI: 0.23
 RecName: Full=Creatine kinase B-type; AltName: =ull=B-CK; AltName: Full=Creatine kinase B =hain
      Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Unique  Peptide
 113  759.3526  758.3453  758.3347  0.0106 0  36  0.4 1       R.DWPDAR.G
 607  983.4736  982.4663  982.4621  0.0042 0  43  0.047 1       R.GIWHNDNK.T 608 609 610 611
 824  1302.6368  1301.6296  1301.6285  0.0010 0  49  0.011 2  U    K.GQSIDDLMPAQK.- 821 825
 828  1318.6257  1317.6185  1317.6235  -0.0050 0  (12) 54 4  U    K.GQSIDDLMPAQK.-
 1078  1964.9618  1963.9545  1963.9236  0.0309 0  9  53 2  U    R.GTGGVDTAAVGGVFDVSNADR.L 1079
5.    gi|3183536    Mass: 4=054    Score: 68    =nbsp;Matches: 6(0)  Sequences: 2(0)
 RecName: Full=Creatine kinase S-type, =itochondrial; AltName: Full=Basic-type mitochondrial creatine kinase; =hort=Mib-CK; AltName: Full=Sarcomeric mitochondrial creatine kinase; =hort=S-MtCK; Flags: Precursor
      Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Unique  Peptide
 113  759.3526  758.3453  758.3347  0.0106 0  36  0.4 1       R.DWPDAR.G
 609  983.4780  982.4708  982.4621  0.0087 0  31  0.83 2       R.GIWHNNDK.T 607 608 610 611
 
      Proteins matching the same set of peptides:
      gi|268370038    Mass: =47068    Score: 68   &nbs=; Matches: 6(0)  Sequences: 2(0)<=TT>
 creatine kinase S-type, mitochondrial [Gallus gallus]
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Page 2 of 2
12/04/2013mhtml:file://C:\Users\farleych\Desktop\Select Summary Report (__-data-20120629-F107200_dat).mht
